BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 675] [Cited by in F6Publishing: 577] [Article Influence: 84.4] [Reference Citation Analysis]
Number Citing Articles
1 Choi SY, Choi S, Kang B, Choe BH, Lee YJ, Park JH, Kim YB, Kim JY, Lee K, Lee KJ, Kang KS, Lee YM, Kim HJ, Kang Y, Jang HJ, Yi DY, Hong SJ, Choi YJ, Hong J, Kim SC. Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era. J Korean Med Sci 2022;37:e279. [PMID: 36163477 DOI: 10.3346/jkms.2022.37.e279] [Reference Citation Analysis]
2 Verburgt CM, Dunn KA, Ghiboub M, Lewis JD, Wine E, Sigall Boneh R, Gerasimidis K, Shamir R, Penny S, Pinto DM, Cohen A, Bjorndahl P, Svolos V, Bielawski JP, Benninga MA, de Jonge WJ, Van Limbergen JE. Successful Dietary Therapy in Paediatric Crohn’s Disease is Associated with Shifts in Bacterial Dysbiosis and Inflammatory Metabotype Towards Healthy Controls. Journal of Crohn's and Colitis 2022. [DOI: 10.1093/ecco-jcc/jjac105] [Reference Citation Analysis]
3 Pulvirenti G, Sortino V, Manti S, Parisi GF, Papale M, Giallongo A, Leonardi S. Pathogenesis, diagnosis, dietary management, and prevention of gastrointestinal disorders in the paediatric population. Ital J Pediatr 2022;48. [DOI: 10.1186/s13052-022-01366-8] [Reference Citation Analysis]
4 Adler J, Colletti RB, Noonan L, Berzin TM, Cheifetz AS, Conklin LS, Hoops TC, Huang CS, Lewis B, Mishkin DS, Hung Lo K, Xiao Y, Volger S. Validating the Simplified Endoscopic Mucosal Assessment for Crohn's Disease: A Novel Method for Assessing Disease Activity. Inflamm Bowel Dis 2022:izac183. [PMID: 36049024 DOI: 10.1093/ibd/izac183] [Reference Citation Analysis]
5 Höyhtyä M, Korpela K, Saqib S, Junkkari S, Nissilä E, Nikkonen A, Dikareva E, Salonen A, de Vos WM, Kolho KL. Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac182. [PMID: 36040412 DOI: 10.1093/ibd/izac182] [Reference Citation Analysis]
6 Lerchova T, Hradsky O, Kulich M, Veres G, Dias JA, Sładek M, Kolacek S, Van Biervliet S, Melek J, Serban DE, Winther K, de Meij T, Schwarz J, Kolho KL, Escher JC, Bronsky J. Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN. Pediatr Res 2022. [PMID: 36008595 DOI: 10.1038/s41390-022-02270-x] [Reference Citation Analysis]
7 Sigurdsson GV, Schmidt S, Mellström D, Ohlsson C, Saalman R, Lorentzon M. Young Adult Male Patients With Childhood-onset IBD Have Increased Risks of Compromised Cortical and Trabecular Bone Microstructures. Inflamm Bowel Dis 2022:izac181. [PMID: 35993421 DOI: 10.1093/ibd/izac181] [Reference Citation Analysis]
8 Alhadab AA, AlMahamed SN, Hassan IE, Hammo AH. The impact of inflammatory bowel diseases on the quality of life of Saudi pediatric patients: A cross-sectional study. Saudi J Gastroenterol 2022. [PMID: 35946259 DOI: 10.4103/sjg.sjg_162_22] [Reference Citation Analysis]
9 Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35906289 DOI: 10.1038/s41575-022-00658-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Núñez-sánchez MA, Melgar S, O’donoghue K, Martínez-sánchez MA, Fernández-ruiz VE, Ferrer-gómez M, Ruiz-alcaraz AJ, Ramos-molina B. Crohn’s Disease, Host–Microbiota Interactions, and Immunonutrition: Dietary Strategies Targeting Gut Microbiome as Novel Therapeutic Approaches. IJMS 2022;23:8361. [DOI: 10.3390/ijms23158361] [Reference Citation Analysis]
11 Martins AL, Fróes RSB, Zago-Gomes MP. Prevalence, phenotype and medication for the pediatric inflammatory bowel disease population of a state in Southeastern Brazil. World J Clin Pediatr 2022; 11(4): 341-350 [DOI: 10.5409/wjcp.v11.i4.341] [Reference Citation Analysis]
12 Shao S, Huang M, Zhang H, Peng G, Song M, Liu J, Xu D. A Retrospective Analysis of Clinical Features and Treatment of the Inflammatory Bowel Disease in China. J Inflamm Res 2022;15:3587-97. [PMID: 35757458 DOI: 10.2147/JIR.S353329] [Reference Citation Analysis]
13 Bak MTJ, Ruiterkamp MFE, van Ruler O, Campmans-Kuijpers MJE, Bongers BC, van Meeteren NLU, van der Woude CJ, Stassen LPS, de Vries AC. Prehabilitation prior to intestinal resection in Crohn’s disease patients: An opinion review. World J Gastroenterol 2022; 28(22): 2403-2416 [DOI: 10.3748/wjg.v28.i22.2403] [Reference Citation Analysis]
14 Jongsma MME, Vuijk SA, Cozijnsen MA, van Pieterson M, Norbruis OF, Groeneweg M, Wolters VM, van Wering HM, Hojsak I, Kolho K, van Wijk MP, Teklenburg-roord STA, de Meij TGJ, Escher JC, de Ridder L. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease. Eur J Pediatr. [DOI: 10.1007/s00431-022-04496-7] [Reference Citation Analysis]
15 Gana JC, Sepúlveda A, Orlanski-meyer E, Villarroel del Pino LA, de la Piedra Bustamante MJ, Olivares Labbe MT; Cochrane Gut Group. Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn’s disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014497] [Reference Citation Analysis]
16 Gu P, Feagins LA. Diet in the Pathogenesis and Management of Crohn's Disease. Gastroenterol Clin North Am 2022;51:319-35. [PMID: 35595417 DOI: 10.1016/j.gtc.2021.12.008] [Reference Citation Analysis]
17 Fitzpatrick JA, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35577903 DOI: 10.1038/s41575-022-00619-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
18 Jiang J, Chen L, Chen Y, Chen H. Exclusive enteral nutrition remodels the intestinal flora in patients with active Crohn's disease. BMC Gastroenterol 2022;22:212. [PMID: 35501724 DOI: 10.1186/s12876-022-02293-y] [Reference Citation Analysis]
19 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]
20 Giorgio V, Margiotta G, Stella G, Di Cicco F, Leoni C, Proli F, Zampino G, Gasbarrini A, Onesimo R. Intestinal Permeability in Children with Functional Gastrointestinal Disorders: The Effects of Diet. Nutrients 2022;14:1578. [DOI: 10.3390/nu14081578] [Reference Citation Analysis]
21 Peters S, Cantez S, De Laffolie J; CEDATA Study Group. Implementation of exclusive enteral nutrition in pediatric patients with Crohn’s disease—results of a survey of CEDATA-GPGE reporting centers. Mol Cell Pediatr 2022;9. [DOI: 10.1186/s40348-022-00139-x] [Reference Citation Analysis]
22 Dipasquale V, Cicala G, Spina E, Romano C. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Front Pharmacol 2022;13:846151. [PMID: 35370732 DOI: 10.3389/fphar.2022.846151] [Reference Citation Analysis]
23 Mitchel EB, Rosh JR. Pediatric Management of Crohn’s Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.013] [Reference Citation Analysis]
24 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
26 Li H, Xie L, Yao H, Zhang L, Liang S, Lyu W. Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn’s Disease. IMCRJ 2022;Volume 15:117-24. [DOI: 10.2147/imcrj.s346159] [Reference Citation Analysis]
27 Śledzińska K, Landowski P, Żmijewski MA, Kamińska B, Kowalski K, Liberek A. Diet, Sun, Physical Activity and Vitamin D Status in Children with Inflammatory Bowel Disease. Nutrients 2022;14:1029. [PMID: 35268001 DOI: 10.3390/nu14051029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Roncoroni L, Gori R, Elli L, Tontini GE, Doneda L, Norsa L, Cuomo M, Lombardo V, Scricciolo A, Caprioli F, Costantino A, Scaramella L, Vecchi M. Nutrition in Patients with Inflammatory Bowel Diseases: A Narrative Review. Nutrients 2022;14:751. [DOI: 10.3390/nu14040751] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
29 Limketkai BN, Hamideh M, Shah R, Sauk JS, Jaffe N. Dietary Patterns and Their Association With Symptoms Activity in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab335] [Reference Citation Analysis]
30 Wasilewska A, Ponanta-gawron K, Burtan B, Stephen Chandra Sagaran C, Duplaga M, Kowalska-duplaga K. Exclusive Enteral Nutrition Remission Induction Treatment Influence on Transient Hypertransaminasemia in Children with Newly Onset Crohn's Disease. Journal of Medicinal Food. [DOI: 10.1089/jmf.2021.0069] [Reference Citation Analysis]
31 Kim ES, Choi S, Choi SY, Park JH, Choe BH, Lee SY, Kim MJ, Choe YH, Kang B. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine. Aliment Pharmacol Ther 2022. [PMID: 35032047 DOI: 10.1111/apt.16769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Williams I, Pandey S, Haller W, Huynh HQ, Chan A, Düeker G, Bettels R, Peyrin-biroulet L, Dike CR, Degeeter C, Smith D, Al Eisa N, Platt N, Marquardt T, Schwerd T, Platt FM, Uhlig HH. Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C. Wellcome Open Res 2022;7:11. [DOI: 10.12688/wellcomeopenres.16986.1] [Reference Citation Analysis]
33 de Sire R, Nardone OM, Testa A, Calabrese G, Caiazzo A, Castiglione F. Exclusive Enteral Nutrition in Adult Crohn's Disease: an Overview of Clinical Practice and Perceived Barriers. Clin Exp Gastroenterol 2021;14:493-501. [PMID: 35002274 DOI: 10.2147/CEG.S267172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Matuszczyk M, Meglicka M, Landowski P, Czkwianianc E, Sordyl B, Szymańska E, Kierkuś J. Oral exclusive enteral nutrition for induction of clinical remission, mucosal healing, and improvement of nutritional status and growth velocity in children with active Crohn's disease - a prospective multicentre trial. Prz Gastroenterol 2021;16:346-51. [PMID: 34976243 DOI: 10.5114/pg.2021.111483] [Reference Citation Analysis]
35 D'Arcangelo G, Abi Nader E, Charbit-Henrion F, Talbotec C, Goulet O, Ruemmele FM, Pigneur B. Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study. J Pediatr Gastroenterol Nutr 2022;74:79-84. [PMID: 34962501 DOI: 10.1097/MPG.0000000000003301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut 2022;71:34-42. [PMID: 33384335 DOI: 10.1136/gutjnl-2020-322339] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
37 Ceballos D, Hernández-Camba A, Ramos L. Diet and microbiome in the beginning of the sequence of gut inflammation. World J Clin Cases 2021; 9(36): 11122-11147 [DOI: 10.12998/wjcc.v9.i36.11122] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
38 Sassine S, Zekhnine S, Qaddouri M, Djani L, Cambron-Asselin C, Savoie-Robichaud M, Lin YF, Grzywacz K, Groleau V, Dirks M, Drouin É, Halac U, Marchand V, Girard C, Courbette O, Patey N, Dal Soglio D, Deslandres C, Jantchou P. Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study. JGH Open 2021;5:1373-81. [PMID: 34950781 DOI: 10.1002/jgh3.12684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Gordon-Dixon A, Gore-Rodney J, Hampal R, Ross R, Miah A, Amorim Adegboye AR, Grimes CE. The role of exclusive enteral nutrition in the pre-operative optimisation of adult patients with Crohn's disease. A systematic review. Clin Nutr ESPEN 2021;46:99-105. [PMID: 34857254 DOI: 10.1016/j.clnesp.2021.09.723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Gkikas K, Logan M, Nichols B, Ijaz UZ, Clark CM, Svolos V, Gervais L, Duncan H, Garrick V, Curtis L, Buchanan E, Cardigan T, Armstrong L, Delahunty C, Flynn DM, Barclay AR, Tayler R, Milling S, Hansen R, Russell RK, Gerasimidis K. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn's disease: a pilot study. BMC Gastroenterol 2021;21:454. [PMID: 34861829 DOI: 10.1186/s12876-021-02029-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Herman R, Dumnicka P, Pieczarkowski S, Fyderek K. Induction of Remission in Pediatric Crohn's Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index. J Clin Med 2021;10:5613. [PMID: 34884315 DOI: 10.3390/jcm10235613] [Reference Citation Analysis]
42 Fang SB, Song YQ, Zhang CY, Wang LB. Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis. World J Pediatr 2021. [PMID: 34800281 DOI: 10.1007/s12519-021-00486-1] [Reference Citation Analysis]
43 Eindor-Abarbanel A, Healey GR, Jacobson K. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood. Int J Mol Sci 2021;22:12506. [PMID: 34830388 DOI: 10.3390/ijms222212506] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Szczubełek M, Pomorska K, Korólczyk-Kowalczyk M, Lewandowski K, Kaniewska M, Rydzewska G. Effectiveness of Crohn's Disease Exclusion Diet for Induction of Remission in Crohn's Disease Adult Patients. Nutrients 2021;13:4112. [PMID: 34836367 DOI: 10.3390/nu13114112] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
45 Atia O, Orlanski-Meyer E, Lujan R, Ledderman N, Greenfeld S, Kariv R, Daher S, Yanai H, Loewenberg Weisband Y, Gabay H, Matz E, Nevo D, Israeli E, Schwartz D, Chowers Y, Dotan I, Turner D. Improved outcomes of pediatric and adult Crohn's disease and association with emerging use of biologics - a nationwide study from the epi-IIRN. J Crohns Colitis 2021:jjab204. [PMID: 34791083 DOI: 10.1093/ecco-jcc/jjab204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Lee WS, Song ZL, Wong SY, Gan CW, Koay ZL, Em JM, Chong SY, Lim CB, Wong SY, Chew KS, Kam CC. Environmental risk factors for inflammatory bowel disease: A case control study in Southeast Asian children. J Paediatr Child Health 2021. [PMID: 34761458 DOI: 10.1111/jpc.15830] [Reference Citation Analysis]
47 Cantarelli E, Baccelli F, Simonini G, Alvisi P. Chronic Recurrent Multifocal Osteomyelitis Associated with Crohn Disease: A Potential Role of Exclusion Diet? Comment on Starz et al. The Modification of the Gut Microbiota via Selected Specific Diets in Patients with Crohn's Disease. Nutrients 2021, 13, 2125. Nutrients 2021;13:4005. [PMID: 34836261 DOI: 10.3390/nu13114005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2021. [PMID: 34751954 DOI: 10.1111/apt.16656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
49 Sasson AN. A whole-food exclusion diet as monotherapy for Crohn's disease. Lancet Gastroenterol Hepatol 2022;7:6-7. [PMID: 34739864 DOI: 10.1016/S2468-1253(21)00335-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Li S, Li P, Sun H, Hu W, Hu S, Chen Y, Lv M. Medication Belief is Associated with Improved Adherence to Exclusive Enteral Nutrition in Patients with Crohn's Disease. Patient Prefer Adherence 2021;15:2327-34. [PMID: 34703215 DOI: 10.2147/PPA.S330842] [Reference Citation Analysis]
51 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Adler J, Eder SJ, Gebremariam A, French KR, Moncion I, Singer AAM, Bass LM, Moran CJ, Picoraro JA, Moses J, Lewis JD, Sandberg KC, Mar SJ, Ebach DR, Saeed SA, Rosh JR, Neef HC, Kaplan JL, Goyal A, Del Rosario JF, Zacur GM. Development and Testing of a New Simplified Endoscopic Mucosal Assessment for Crohn's Disease: The SEMA-CD. Inflamm Bowel Dis 2021;27:1585-92. [PMID: 33382069 DOI: 10.1093/ibd/izaa307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Sherlock ME, Zachos M, Issenman RM, Mulder DJ. Clinical and Laboratory Characteristics Are Associated With Biologic Therapy Use in Pediatric Inflammatory Bowel Disease: A Retrospective Cohort Study. J Can Assoc Gastroenterol 2021;4:e92-e100. [PMID: 34617006 DOI: 10.1093/jcag/gwaa033] [Reference Citation Analysis]
54 Lipstein EA, Brinkman WB, Zhang Y, Hommel KA, Ittenbach RF, Liu C, Denson LA. Decision making about anti-TNF therapy: A pilot trial of a shared decision-making intervention. Patient Educ Couns 2021:S0738-3991(21)00639-X. [PMID: 34629231 DOI: 10.1016/j.pec.2021.09.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
55 Svolos V, Gkikas K, Gerasimidis K. Diet and gut microbiota manipulation for the management of Crohn's disease and ulcerative colitis. Proc Nutr Soc 2021;:1-15. [PMID: 34551834 DOI: 10.1017/S0029665121002846] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
56 Bashir NS, Walters TD, Griffiths AM, Ito S, Ungar WJ. Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease. Inflamm Bowel Dis 2020;26:1239-50. [PMID: 31728510 DOI: 10.1093/ibd/izz267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Lehtomäki J, Nikkonen A, Merras-Salmio L, Hiltunen P, Kolho KL. Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease. Scand J Gastroenterol 2021;:1-6. [PMID: 34546843 DOI: 10.1080/00365521.2021.1977843] [Reference Citation Analysis]
58 Goulet O, Breton A, Coste ME, Dubern B, Ecochard-Dugelay E, Guimber D, Loras-Duclaux I, Abi Nader E, Marinier E, Peretti N, Lambe C. Pediatric Home Parenteral Nutrition in France: A six years national survey. Clin Nutr 2021;40:5278-87. [PMID: 34534896 DOI: 10.1016/j.clnu.2021.08.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
59 de Laffolie J, Zimmer KP, Sohrabi K, Hauer AC. Running Behind "POPO"-Impact of Predictors of Poor Outcome for Treatment Stratification in Pediatric Crohn's Disease. Front Med (Lausanne) 2021;8:644003. [PMID: 34513855 DOI: 10.3389/fmed.2021.644003] [Reference Citation Analysis]
60 Jones CMA, Connors J, Dunn KA, Bielawski JP, Comeau AM, Langille MGI, Van Limbergen J. Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn's Disease. Inflamm Bowel Dis 2020;26:1026-37. [PMID: 31961432 DOI: 10.1093/ibd/izaa001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
61 Yang M, Gu Y, Li L, Liu T, Song X, Sun Y, Cao X, Wang B, Jiang K, Cao H. Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside. Nutrients 2021;13:3143. [PMID: 34579027 DOI: 10.3390/nu13093143] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
62 van Hoeve K, Seyed Tabib NS, Dreesen E, Tops S, Hoffman I, Gils A, Ferrante M, Vermeire S. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. J Pediatr 2022;240:150-157.e4. [PMID: 34481805 DOI: 10.1016/j.jpeds.2021.08.079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
63 Kandavel P, Eder SJ, Adler J; ImproveCareNow Network Pediatric IBD Learning Health System. Reduced Systemic Corticosteroid Use among Pediatric Patients With Inflammatory Bowel Disease in a Large Learning Health System. J Pediatr Gastroenterol Nutr 2021;73:345-51. [PMID: 34415262 DOI: 10.1097/MPG.0000000000003182] [Reference Citation Analysis]
64 Kim ES, Kim D, Yoon Y, Kwon Y, Park S, Kim J, Ahn KM, Ahn S, Choe YH, Kim YJ, Kim MJ. Needs for Increased Awareness of Gastrointestinal Manifestations in Patients With Human Inborn Errors of Immunity. Front Immunol 2021;12:698721. [PMID: 34456911 DOI: 10.3389/fimmu.2021.698721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Abramson A, Frederiksen MR, Vegge A, Jensen B, Poulsen M, Mouridsen B, Jespersen MO, Kirk RK, Windum J, Hubálek F, Water JJ, Fels J, Gunnarsson SB, Bohr A, Straarup EM, Ley MWH, Lu X, Wainer J, Collins J, Tamang S, Ishida K, Hayward A, Herskind P, Buckley ST, Roxhed N, Langer R, Rahbek U, Traverso G. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat Biotechnol 2021. [PMID: 34462588 DOI: 10.1038/s41587-021-01024-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
66 Bhattarai A, Kowalczyk W, Tran TN. A literature review on large intestinal hyperelastic constitutive modeling. Clin Biomech (Bristol, Avon) 2021;88:105445. [PMID: 34416632 DOI: 10.1016/j.clinbiomech.2021.105445] [Reference Citation Analysis]
67 Hokari R, Tomioka A. The role of lymphatics in intestinal inflammation. Inflamm Regen 2021;41:25. [PMID: 34404493 DOI: 10.1186/s41232-021-00175-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Ochi M, Niikura R, Otsubo T, Yamada A, Kawai T, Koike K. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. Int J Colorectal Dis 2021;36:2227-35. [PMID: 34386841 DOI: 10.1007/s00384-021-04007-4] [Reference Citation Analysis]
69 Shao HQ, Tan ZJ. Microbiota-targeted therapeutics in gastrointestinal diseases. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 841-848 [DOI: 10.11569/wcjd.v29.i15.841] [Reference Citation Analysis]
70 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
71 Koretz RL. JPEN Journal Club 64. Incorrect statistics. JPEN J Parenter Enteral Nutr 2021. [PMID: 34346081 DOI: 10.1002/jpen.2245] [Reference Citation Analysis]
72 Niseteo T, Sila S, Trivić I, Mišak Z, Kolaček S, Hojsak I. Modified Crohn's disease exclusion diet is equally effective as exclusive enteral nutrition: Real-world data. Nutr Clin Pract 2021. [PMID: 34339527 DOI: 10.1002/ncp.10752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Hensel KO, Kyrana E, Hadzic N, Mann J, Mieli-Vergani G, Gasparetto M, Heuschkel R, Noble-Jamieson G, Samyn M. Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome. J Pediatr 2021:S0022-3476(21)00739-3. [PMID: 34303727 DOI: 10.1016/j.jpeds.2021.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Kowalska-Duplaga K, Gawlik-Scislo A, Krzesiek E, Jarocka-Cyrta E, Łazowska-Przeorek I, Duplaga M, Banaszkiewicz A. Determinants of disease-specific knowledge among children with inflammatory bowel disease and their parents: A multicentre study. World J Gastroenterol 2021; 27(27): 4468-4480 [PMID: 34366617 DOI: 10.3748/wjg.v27.i27.4468] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Pham T, Sokol H, Halioua B, Pourcel G, Brun M, Pain E, Testa D. Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions. BMC Nutr 2021;7:38. [PMID: 34266484 DOI: 10.1186/s40795-021-00446-y] [Reference Citation Analysis]
76 Chande N, Costello SP, Limketkai BN, Parker CE, Nguyen TM, Macdonald JK, Feagan BG. Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. Inflamm Bowel Dis 2020;26:843-51. [PMID: 31560744 DOI: 10.1093/ibd/izz223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
77 Moses J, Sandberg K, Winberry G, Riera D, DeLozier S, Gupta SK, Reilly N, Park KT, Picoraro J. Clinical Practice Survey of Repeat Endoscopy in Pediatric Inflammatory Bowel Disease in North America. J Pediatr Gastroenterol Nutr 2021;73:61-6. [PMID: 33633082 DOI: 10.1097/MPG.0000000000003100] [Reference Citation Analysis]
78 Yang Q, Tang J, Ding N, Chao K, Li M, Huang Z, Guo H, Chen J, Zhi M, Hu P, Gao X. Twelve-week peptide-based formula therapy may be effective in inducing remission of active Crohn disease among women who are pregnant or preparing for pregnancy. Nutr Clin Pract 2021. [PMID: 34245474 DOI: 10.1002/ncp.10733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Lev-Tzion R, Ben-Moshe T, Abitbol G, Ledder O, Peleg S, Millman P, Shaoul R, Kori M, Assa A, Cohen S, Strich D, Revel-Vilk S, Tiomkin M, Levine A, Sigall Boneh R, Turner D. The Effect of Nutritional Therapy on Bone Mineral Density and Bone Metabolism in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:877-82. [PMID: 33587407 DOI: 10.1097/MPG.0000000000003073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Koninckx CR, Donat E, Benninga MA, Broekaert IJ, Gottrand F, Kolho KL, Lionetti P, Miele E, Orel R, Papadopoulou A, Pienar C, Schäppi MG, Wilschanski M, Thapar N. The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. J Pediatr Gastroenterol Nutr 2021;72:617-40. [PMID: 33716293 DOI: 10.1097/MPG.0000000000003046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
81 Carlsen K, Frederiksen NW, Wewer V. Integration of eHealth Into Pediatric Inflammatory Bowel Disease Care is Safe: 3 Years of Follow-up of Daily Care. J Pediatr Gastroenterol Nutr 2021;72:723-7. [PMID: 33470751 DOI: 10.1097/MPG.0000000000003053] [Reference Citation Analysis]
82 Ahn HJ, Kim YJ, Lee HS, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Kim BJ, Park SH. High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00690-X. [PMID: 34216823 DOI: 10.1016/j.cgh.2021.06.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Healey GR, Tsai K, Schick A, Lisko DJ, Cook L, Vallance BA, Jacobson K. Prebiotic Enriched Exclusive Enteral Nutrition Suppresses Colitis via Gut Microbiome Modulation and Expansion of Anti-inflammatory T Cells in a Mouse Model of Colitis. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00126-0. [PMID: 34214707 DOI: 10.1016/j.jcmgh.2021.06.011] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
84 Tran LC, Bridoux-Henno L, Gastineau S, Dabadie A, Carré E, Hugot JP, Martinez-Vinson C, Mosca A, Coopman S, Lamireau T, Enaud R, Clouzeau H, Bertrand V, Pigneur B, Ruemmele F, Degas V, Breton A, Mas E, Lacotte É, Chaillou-Legault E, Caron N, Languepin J, Willot S, Bouazza A, Spyckerelle C, Dimitrov G, Thomassin N, Djeddi D, Vanrenterghem A, Grandjean C, Viala J, Dupont-Lucas C. Functional abdominal pain disorders and patient- and parent- reported outcomes in children with inflammatory bowel disease in remission. Dig Liver Dis 2021:S1590-8658(21)00308-X. [PMID: 34187767 DOI: 10.1016/j.dld.2021.05.034] [Reference Citation Analysis]
85 Newton L, Delbecque L, Coşkun U, Symonds T, Clegg J, Hunter T. A qualitative study to explore symptoms and impacts of pediatric and adolescent Crohn's disease from patient and caregiver perspective. J Patient Rep Outcomes 2021;5:49. [PMID: 34170423 DOI: 10.1186/s41687-021-00321-1] [Reference Citation Analysis]
86 Di Chio T, Sokollik C, Peroni DG, Hart L, Simonetti G, Righini-Grunder F, Borrelli O. Nutritional Aspects of Pediatric Gastrointestinal Diseases. Nutrients 2021;13:2109. [PMID: 34205445 DOI: 10.3390/nu13062109] [Reference Citation Analysis]
87 Kolho KL. Complexity of paediatric trials restricts effect on clinical practice. Lancet Gastroenterol Hepatol 2021;6:598-9. [PMID: 34153230 DOI: 10.1016/S2468-1253(21)00173-4] [Reference Citation Analysis]
88 Ronel N, Tzion RL, Orlanski-Meyer E, Shteyer E, Guz-Mark A, Assa A, Strich D, Turner D, Ledder O. Clinical Criteria Can Identify Children With Osteopenia in Newly Diagnosed Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:270-5. [PMID: 32810035 DOI: 10.1097/MPG.0000000000002911] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Dhaliwal J, Siddiqui I, Muir J, Rinawi F, Church PC, Walters TD, Griffiths AM. Differentiation of Colonic Inflammatory Bowel Disease: Re-examination of Paediatric Inflammatory Bowel Disease Classes Algorithm With Resected Colon As the Criterion Standard. J Pediatr Gastroenterol Nutr 2020;70:218-24. [PMID: 31978020 DOI: 10.1097/MPG.0000000000002544] [Reference Citation Analysis]
90 Pinto Pais I, Espinheira MC, Trindade E, Amil Dias J. Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. J Pediatr Gastroenterol Nutr 2020;71:12-8. [PMID: 32142005 DOI: 10.1097/MPG.0000000000002704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Harris RE, Duncan H, Buchanan E, Cardigan T, Garrick V, Curtis L, Gervais L, Barclay A, Haddock G, Hansen R, Tayler R, Walker G, Russell RK. Prehabilitation: The Impact of Preoperative Exclusive Enteral Nutrition on Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2020;70:503-7. [PMID: 31880668 DOI: 10.1097/MPG.0000000000002595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Zijlstra M, Jongsma MME, de Vries A, Schaap T, Bloem K, de Ridder L. Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr 2021;72:56-60. [PMID: 32804907 DOI: 10.1097/MPG.0000000000002906] [Reference Citation Analysis]
93 Picoraro JA, Akabas SR, LeLeiko NS. Harmonizing Nutritional Therapies for Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020;70:285-8. [PMID: 31860541 DOI: 10.1097/MPG.0000000000002602] [Reference Citation Analysis]
94 Rubalcava NS, Gadepalli SK. Inflammatory Bowel Disease in Children and Adolescents. Adv Pediatr 2021;68:121-42. [PMID: 34243849 DOI: 10.1016/j.yapd.2021.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Bąk-Drabik K, Adamczyk P, Duda-Wrońska J, Dąbrowska-Piechota D, Jarzumbek A, Kwiecień J. Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine. Gastroenterol Res Pract 2021;2021:9970019. [PMID: 34239556 DOI: 10.1155/2021/9970019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Ma L, Li W, Zhuang N, Yang H, Liu W, Zhou W, Jiang Y, Li J, Zhu Q, Qian J. Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn's disease. Therap Adv Gastroenterol 2021;14:17562848211016259. [PMID: 34178114 DOI: 10.1177/17562848211016259] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
97 Torun A, Hupalowska A, Trzonkowski P, Kierkus J, Pyrzynska B. Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children. Front Immunol 2021;12:642166. [PMID: 34163468 DOI: 10.3389/fimmu.2021.642166] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
98 Akutko K, Stawarski A. Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. J Clin Med 2021;10:2466. [PMID: 34199428 DOI: 10.3390/jcm10112466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
99 Harris RE, Hegde V, Curtis L, Garrick V, Gervais L, Armstrong L, Delahunty C, Eccleston A, Al-Hourani G, Flynn DM, Merrick V, Barclay AR, Tayler R, Hansen R, Russell RK. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. J Pediatr Gastroenterol Nutr 2021;73:358-62. [PMID: 34091548 DOI: 10.1097/MPG.0000000000003197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Jochmann A, Trachsel D, Hammer J. Inflammatory bowel disease and the lung in paediatric patients. Breathe (Sheff) 2021;17:200269. [PMID: 34295391 DOI: 10.1183/20734735.0269-2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Sahu P, Kedia S, Ahuja V, Tandon RK. Diet and nutrition in the management of inflammatory bowel disease. Indian J Gastroenterol 2021;40:253-64. [PMID: 34037954 DOI: 10.1007/s12664-021-01163-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Gerasimidis K, Godny L, Sigall-boneh R, Svolos V, Wall C, Halmos E. Current recommendations on the role of diet in the aetiology and management of IBD. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2020-101429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
103 Choi S, Moon W. [Pediatric-onset Inflammatory Bowel Disease: What Are Different from Adult in the Treatment?]. Korean J Gastroenterol 2021;77:220-6. [PMID: 34035199 DOI: 10.4166/kjg.2021.067] [Reference Citation Analysis]
104 Lawrence LS, Heider A, Singer AAM, Neef HC, Adler J. Granulomas in Diagnostic Biopsies Associated With High Risk of Crohn's Complications-But May Be Preventable. Inflamm Bowel Dis 2021:izab109. [PMID: 33999198 DOI: 10.1093/ibd/izab109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Ahola Kohut S, Martincevic I, Turrell SL, Church PC, Walters TD, Weiser N, Iuliano A. Online Acceptance and Commitment Therapy and Nutrition Workshop for Parents of Children with Inflammatory Bowel Disease: Feasibility, Acceptability, and Initial Effectiveness. Children (Basel) 2021;8:396. [PMID: 34069305 DOI: 10.3390/children8050396] [Reference Citation Analysis]
106 Caio G, Lungaro L, Caputo F, Zoli E, Giancola F, Chiarioni G, De Giorgio R, Zoli G. Nutritional Treatment in Crohn's Disease. Nutrients 2021;13:1628. [PMID: 34066229 DOI: 10.3390/nu13051628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Lucafò M, Curci D, Bramuzzo M, Alvisi P, Martelossi S, Silvestri T, Guastalla V, Labriola F, Stocco G, Decorti G. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. Front Pediatr 2021;9:646671. [PMID: 34017806 DOI: 10.3389/fped.2021.646671] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
108 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
109 Corrêa FF, Sdepanian VL. BODY IRON STATUS INDICATORS AND INFLAMMATION INDICATORS DURING INFLAMMATORY BOWEL DISEASE THERAPY IN CHILDREN AND ADOLESCENTES. Arq Gastroenterol 2021;58:48-54. [PMID: 33909796 DOI: 10.1590/S0004-2803.202100000-09] [Reference Citation Analysis]
110 Walker R, Ferris K, Scott M, McMahon N, Szabo A, Dick AC, Christie S, Mallett P. Perioral swelling in a previously well child. Arch Dis Child Educ Pract Ed 2021:edpract-2020-319223. [PMID: 33931499 DOI: 10.1136/archdischild-2020-319223] [Reference Citation Analysis]
111 Socha-Banasiak A, Sputa-Grzegrzółka P, Grzegrzółka J, Pacześ K, Dzięgiel P, Sordyl B, Romanowicz H, Czkwianianc E. Metallothioneins in Inflammatory Bowel Diseases: Importance in Pathogenesis and Potential Therapy Target. Can J Gastroenterol Hepatol 2021;2021:6665697. [PMID: 33987146 DOI: 10.1155/2021/6665697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Bertani L, Ribaldone DG, Bellini M, Mumolo MG, Costa F. Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions? Nutrients 2021;13:1387. [PMID: 33924119 DOI: 10.3390/nu13041387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
114 Yamamoto M, Shanmuganathan M, Hart L, Pai N, Britz-McKibbin P. Urinary Metabolites Enable Differential Diagnosis and Therapeutic Monitoring of Pediatric Inflammatory Bowel Disease. Metabolites 2021;11:245. [PMID: 33921143 DOI: 10.3390/metabo11040245] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
115 Atia O, Asayag N, Focht G, Lujan R, Ledder O, Greenfeld S, Kariv R, Dotan I, Gabay H, Balicer R, Haklai Z, Nevo D, Turner D. Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epiIIRN Cohort. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00395-5. [PMID: 33845216 DOI: 10.1016/j.cgh.2021.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
116 Lund K, Larsen MD, Knudsen T, Kjeldsen J, Nielsen RG, Mertz Nørgård B. Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study. J Crohns Colitis 2021;15:575-82. [PMID: 32926166 DOI: 10.1093/ecco-jcc/jjaa188] [Reference Citation Analysis]
117 Limketkai BN, Gordon M, Mutlu EA, De Silva PS, Lewis JD. Diet Therapy for Inflammatory Bowel Diseases: A Call to the Dining Table. Inflamm Bowel Dis 2020;26:510-4. [PMID: 31819987 DOI: 10.1093/ibd/izz297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
118 Dembiński Ł, Stelmaszczyk-Emmel A, Sznurkowska K, Szlagatys-Sidorkiewicz A, Radzikowski A, Banaszkiewicz A. Immunogenicity of cholera vaccination in children with inflammatory bowel disease. Hum Vaccin Immunother 2021;17:2586-92. [PMID: 33794737 DOI: 10.1080/21645515.2021.1884475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Li H, Mo Y, Huang C, Ren Q, Xia X, Nan X, Shuai X, Meng X. An MSCT-based radiomics nomogram combined with clinical factors can identify Crohn's disease and ulcerative colitis. Ann Transl Med 2021;9:572. [PMID: 33987270 DOI: 10.21037/atm-21-1023] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
120 Vernon-roberts A, Gearry RB, Day AS. Overview of Self-Management Skills and Associated Assessment Tools for Children with Inflammatory Bowel Disease. GastrointestDisord 2021;3:61-77. [DOI: 10.3390/gidisord3020007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Campmans-Kuijpers MJE, Dijkstra G. Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID). Nutrients 2021;13:1067. [PMID: 33806061 DOI: 10.3390/nu13041067] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
122 Cheng H, Ma Z, Yu B, Liu X, Tian C, Zhong X, Zhao L. Quality assessment of clinical guidelines on probiotics therapy in children with IBD using the AGREE II instrument. J Clin Pharm Ther 2021;46:1155-65. [PMID: 33768598 DOI: 10.1111/jcpt.13422] [Reference Citation Analysis]
123 Dipasquale V, Passanisi S, Cucinotta U, Cascio A, Romano C. Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease. Ital J Pediatr 2021;47:71. [PMID: 33761992 DOI: 10.1186/s13052-021-01020-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
124 Giannoudaki E, Gargan S, Hussey S, Long A, Walsh PT. Opportunities to Target T Cell Trafficking in Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:640497. [PMID: 33816403 DOI: 10.3389/fped.2021.640497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Villemonteix J, Guérin-El Khourouj V, Hugot JP, Giardini C, Carcelain G, Martinez-Vinson C. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases. Biologicals 2021;70:17-21. [PMID: 33676831 DOI: 10.1016/j.biologicals.2021.02.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Adamina M, Gerasimidis K, Sigall-Boneh R, Zmora O, de Buck van Overstraeten A, Campmans-Kuijpers M, Ellul P, Katsanos K, Kotze PG, Noor N, Schäfli-Thurnherr J, Vavricka S, Wall C, Wierdsma N, Yassin N, Lomer M. Perioperative Dietary Therapy in Inflammatory Bowel Disease.J Crohns Colitis. 2020;14:431-444. [PMID: 31550347 DOI: 10.1093/ecco-jcc/jjz160] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
127 Rodriguez-Sillke Y, Visekruna A, Glauben R, Siegmund B, Steinhoff U. Recognition of food antigens by the mucosal and systemic immune system: Consequences for intestinal development and homeostasis. Int J Med Microbiol 2021;311:151493. [PMID: 33652373 DOI: 10.1016/j.ijmm.2021.151493] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
128 Cucinotta U, Romano C, Dipasquale V. Diet and Nutrition in Pediatric Inflammatory Bowel Diseases. Nutrients 2021;13:655. [PMID: 33671453 DOI: 10.3390/nu13020655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
129 Jagt JZ, Pothof CD, Buiter HJC, van Limbergen JE, van Wijk MP, Benninga MA, de Boer NKH, de Meij TGJ. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. Dig Dis Sci 2021. [PMID: 33532972 DOI: 10.1007/s10620-021-06836-3] [Reference Citation Analysis]
130 Modrackova N, Copova I, Stovicek A, Makovska M, Schierova D, Mrazek J, Sabolova M, Vlkova E, Hradsky O, Bronsky J, Nevoral J, Neuzil-bunesova V. Microbial shifts of faecal microbiota using enteral nutrition in vitro. Journal of Functional Foods 2021;77:104330. [DOI: 10.1016/j.jff.2020.104330] [Reference Citation Analysis]
131 Van Limbergen JE, Koot BGP, de Winter JP. Fool me once… treatment exposure to achieve remission in pediatric IBD. Eur J Pediatr 2020;179:1921-4. [PMID: 33135091 DOI: 10.1007/s00431-020-03862-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Neville JJ, Macdonald A, Fell J, Choudhry M, Haddad M. Therapeutic strategies for stricturing Crohn's disease in childhood: a systematic review. Pediatr Surg Int 2021;37:569-77. [PMID: 33492462 DOI: 10.1007/s00383-020-04848-0] [Reference Citation Analysis]
133 Alsufyani HA, Mosli MM, Saadah OI. Body composition profile of children and adolescent patients with inflammatory bowel disease. Int J Clin Pract 2021;75:e14023. [PMID: 33448027 DOI: 10.1111/ijcp.14023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 de Castro MM, Pascoal LB, Steigleder KM, Siqueira BP, Corona LP, Ayrizono MLS, Milanski M, Leal RF. Role of diet and nutrition in inflammatory bowel disease. World J Exp Med 2021; 11(1): 1-16 [PMID: 33585174 DOI: 10.5493/wjem.v11.i1.1] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
135 Naqvi SA, Taylor LM, Panaccione R, Ghosh S, Barkema HW, Hotte N, Shommu N, Kaur S, Reimer RA, Madsen KL, Raman M. Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. Sci Rep 2021;11:1674. [PMID: 33462267 DOI: 10.1038/s41598-020-80924-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
136 Sahu P, Kedia S, Vuyyuru SK, Bajaj A, Markandey M, Singh N, Singh M, Kante B, Kumar P, Ranjan M, Sahni P, Panwar R, Sharma R, Das P, Makharia G, Travis SPL, Ahuja V. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment Pharmacol Ther 2021;53:568-76. [PMID: 33440046 DOI: 10.1111/apt.16249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Verburgt CM, Ghiboub M, Benninga MA, de Jonge WJ, Van Limbergen JE. Nutritional Therapy Strategies in Pediatric Crohn's Disease. Nutrients 2021;13:212. [PMID: 33450982 DOI: 10.3390/nu13010212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Cao Y, Su Q, Zhang B, Shen F, Li S. Efficacy of stem cells therapy for Crohn's fistula: a meta-analysis and systematic review. Stem Cell Res Ther 2021;12:32. [PMID: 33413661 DOI: 10.1186/s13287-020-02095-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
139 Kim PH, Kim SH, Cho YA, Yoon HM, Lee JS, Jung AY, Oh SH, Kim DY, Namgoong JM, Kim KM. Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn's Disease Patients. J Crohns Colitis 2021;15:1152-60. [PMID: 33411884 DOI: 10.1093/ecco-jcc/jjab004] [Reference Citation Analysis]
140 Ashton JJ, Green Z, Young A, Borca F, Coelho T, Batra A, Afzal NA, Ennis S, Johnson MJ, Beattie RM. Growth failure is rare in a contemporary cohort of paediatric inflammatory bowel disease patients. Acta Paediatr 2021;110:326-34. [PMID: 32485032 DOI: 10.1111/apa.15383] [Reference Citation Analysis]
141 Elbanoni O, Altawaty A. Steroid-Induced acute psychosis in an 8-year-old child with inflammatory bowel disease. Ibnosina J Med Biomed Sci 2021;13:91. [DOI: 10.4103/ijmbs.ijmbs_21_21] [Reference Citation Analysis]
142 Cococcioni L, Panelli S, Varotto-boccazzi I, Carlo DD, Pistone D, Leccese G, Zuccotti GV, Comandatore F. IBDs and the pediatric age: Their peculiarities and the involvement of the microbiota. Digestive and Liver Disease 2021;53:17-25. [DOI: 10.1016/j.dld.2020.10.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Wark G, Samocha-Bonet D, Ghaly S, Danta M. The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. Nutrients 2020;13:E135. [PMID: 33396537 DOI: 10.3390/nu13010135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
144 Yao J, Jiang X, You JHS. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis. J Gastroenterol Hepatol 2021;36:2397-407. [PMID: 33326123 DOI: 10.1111/jgh.15373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
145 Giardino S, Bava C, Arrigo S, Pierri F, Gandullia P, Coccia C, Faraci M. Thalidomide as treatment of crohn-like disease occurred after allogeneic hematopoietic stem cell transplantation in a pediatric patient. Pediatr Transplant 2021;25:e13941. [PMID: 33314581 DOI: 10.1111/petr.13941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 van den Bosch BJ, Coenen MJ. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021;22:55-66. [PMID: 33305616 DOI: 10.2217/pgs-2020-0095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Herrador-López M, Martín-Masot R, Navas-López VM. EEN Yesterday and Today … CDED Today and Tomorrow. Nutrients 2020;12:E3793. [PMID: 33322060 DOI: 10.3390/nu12123793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
148 Dupont-Lucas C, Marion-Letellier R, Pala M, Guerin C, Amamou A, Jarbeau M, Bôle-Feysot C, Nicol L, David A, Aziz M, Colasse E, Savoye-Collet C, Savoye G. A polymeric diet rich in transforming growth factor beta 2 does not reduce inflammation in chronic 2,4,6-trinitrobenzene sulfonic acid colitis in pre-pubertal rats. BMC Gastroenterol 2020;20:416. [PMID: 33302890 DOI: 10.1186/s12876-020-01574-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
149 Ley D, Dehak R, de Luca A, Turquet A, Dauchet L, Bouteloup C, Danel N, Delarue J, Hasselman M, Jesus P, Fayemendy P, Pham S, Piton G, Raynard B, Gower C, Hennequin V, Guimber D, Lescut D. Épidémiologie de la nutrition entérale à domicile chez l’enfant en France. Nutrition Clinique et Métabolisme 2020;34:295-300. [DOI: 10.1016/j.nupar.2020.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Ha C, Kim ES, Kwon Y, Choe YH, Kim MJ, Lee SY. The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn's Disease. Pharmgenomics Pers Med 2020;13:665-71. [PMID: 33273844 DOI: 10.2147/PGPM.S279446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Roca M, Rodriguez Varela A, Carvajal E, Donat E, Cano F, Armisen A, Vaya MJ, Ekoff H, Hervas D, Rydell N, Ribes-Koninckx C. Fecal calprotectin in healthy children aged 4-16 years. Sci Rep 2020;10:20565. [PMID: 33239728 DOI: 10.1038/s41598-020-77625-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
152 Kim ES, Kwon Y, Choe YH, Kim MJ. Upper gastrointestinal tract involvement is more prevalent in Korean patients with pediatric Crohn's disease than in European patients. Sci Rep 2020;10:19032. [PMID: 33149222 DOI: 10.1038/s41598-020-75938-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
153 Kataria R, Pickett-blakely O. The Mediterranean Diet in Gastrointestinal and Liver Diseases. Curr Treat Options Gastro 2020;18:718-28. [DOI: 10.1007/s11938-020-00318-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Diederen K, Li JV, Donachie GE, de Meij TG, de Waart DR, Hakvoort TBM, Kindermann A, Wagner J, Auyeung V, Te Velde AA, Heinsbroek SEM, Benninga MA, Kinross J, Walker AW, de Jonge WJ, Seppen J. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease. Sci Rep 2020;10:18879. [PMID: 33144591 DOI: 10.1038/s41598-020-75306-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
155 van Hoeve K, Vermeire S. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. Paediatr Drugs 2020;22:449-61. [PMID: 32797366 DOI: 10.1007/s40272-020-00411-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Amaro F, Chiarelli F. Growth and Puberty in Children with Inflammatory Bowel Diseases. Biomedicines 2020;8:E458. [PMID: 33138015 DOI: 10.3390/biomedicines8110458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
157 Gu P, Feagins LA. Dining With Inflammatory Bowel Disease: A Review of the Literature on Diet in the Pathogenesis and Management of IBD. Inflamm Bowel Dis 2020;26:181-91. [PMID: 31670372 DOI: 10.1093/ibd/izz268] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
158 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignass A, Kucharzik T; Collaborators:. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Z Gastroenterol 2020;58:982-1002. [DOI: 10.1055/a-1234-8079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
159 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 100] [Cited by in F6Publishing: 74] [Article Influence: 50.0] [Reference Citation Analysis]
160 Solomon S, Park E, Picoraro JA. Making Decisions about Dietary Therapy in Inflammatory Bowel Disease. GastrointestDisord 2020;2:353-65. [DOI: 10.3390/gidisord2040032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Erős A, Dohos D, Veres G, Tárnok A, Vincze Á, Tészás A, Zádori N, Gede N, Hegyi P, Sarlós P. Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD). BMJ Open 2020;10:e038410. [PMID: 33028560 DOI: 10.1136/bmjopen-2020-038410] [Reference Citation Analysis]
162 Haisma SM, Verkade HJ, Scheenstra R, van der Doef HPJ, Bodewes FAJA, van Rheenen PF. Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:466-73. [PMID: 31365486 DOI: 10.1097/MPG.0000000000002458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
163 Rinawi F, Ricciuto A, Church PC, Frost K, Crowley E, Walters TD, Griffiths AM. Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn's Disease. Inflamm Bowel Dis 2021;27:1079-87. [PMID: 32978946 DOI: 10.1093/ibd/izaa247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
164 de Laffolie J, Schwerd T, Simon A, Pauli M, Broekaert I, Classen M, Posovszky C, Schmidt-Choudhury A; im Namen und Auftrag der AGs CEDATA und AG Ernährung und Diätetik/Ernährungsmedizin der GPGE. [Crohn's Disease Exclusion Diet - an alternative to exlusive enteral nutritional therapy in children and adolescents with Crohn's disease? Statement of the GPGE working groups CEDATA and Nutrition/Nutrition Medicine]. Z Gastroenterol 2020;58:890-4. [PMID: 32947634 DOI: 10.1055/a-1199-6751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Mutanen A, Pakarinen MP. Perianal Crohn's Disease in Children and Adolescents. Eur J Pediatr Surg 2020;30:395-400. [PMID: 32942329 DOI: 10.1055/s-0040-1716724] [Reference Citation Analysis]
166 Ghiboub M, Verburgt CM, Sovran B, Benninga MA, de Jonge WJ, Van Limbergen JE. Nutritional Therapy to Modulate Tryptophan Metabolism and Aryl Hydrocarbon-Receptor Signaling Activation in Human Diseases. Nutrients 2020;12:E2846. [PMID: 32957545 DOI: 10.3390/nu12092846] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
167 Chan KJ, Song ZL, Chew KS, Ng RT, Mohd Taib SH, Lee WS. Exclusive enteral nutrition is effective and feasible as primary induction and re-induction therapy in Asian children with Crohn's disease. J Paediatr Child Health 2021;57:239-45. [PMID: 32936506 DOI: 10.1111/jpc.15184] [Reference Citation Analysis]
168 Bourchany A, Gilletta De Saint-Joseph C, Breton A, Barreau F, Mas E. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Curr Opin Pharmacol 2020;54:51-8. [PMID: 32947075 DOI: 10.1016/j.coph.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;68:847-53. [PMID: 30633108 DOI: 10.1097/MPG.0000000000002265] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
170 Taylor H, Serrano-Contreras JI, McDonald JAK, Epstein J, Fell JM, Seoane RC, Li JV, Marchesi JR, Hart AL. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease. Aliment Pharmacol Ther 2020;52:1491-502. [PMID: 32929796 DOI: 10.1111/apt.16086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
171 Salamon D, Gosiewski T, Krawczyk A, Sroka-Oleksiak A, Duplaga M, Fyderek K, Kowalska-Duplaga K. Quantitative changes in selected bacteria in the stool during the treatment of Crohn's disease. Adv Med Sci 2020;65:348-53. [PMID: 32590155 DOI: 10.1016/j.advms.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
172 Gupta N, Lustig RH, Andrews H, Gokhale R, Goyal A, Patel AS, Guthery S, Sylvester F, Siebold L, Leu CS. Clinical Variables Associated With Statural Growth in Pediatric Crohn's Disease Differ by Sex (The Growth Study). Inflamm Bowel Dis 2021;27:751-9. [PMID: 32860033 DOI: 10.1093/ibd/izaa220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Arai K. Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists. Pediatr Gastroenterol Hepatol Nutr 2020;23:411-22. [PMID: 32953636 DOI: 10.5223/pghn.2020.23.5.411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Miyoshi J, Saito D, Nakamura M, Miura M, Mitsui T, Kudo T, Murakami S, Matsuura M, Hisamatsu T. Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals. Gastroenterol Res Pract 2020;2020:7086939. [PMID: 32831827 DOI: 10.1155/2020/7086939] [Reference Citation Analysis]
175 Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho KL, Bronsky J, Assa A, Cohen S, Lev-Tzion R, Van Biervliet S, Rizopoulos D, de Meij TGJ, Shouval DS, Wine E, Wolters VM, Martinez-Vinson C, de Ridder L; Paediatric IBD Porto Group of ESPGHAN. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 2020;179:1935-44. [PMID: 32813123 DOI: 10.1007/s00431-020-03750-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
176 El Mouzan M, Alahmadi N, ALSaleeem KA, Assiri A, AlSaleem B, Al Sarkhy A. Prevalence of nutritional disorders in Saudi children with inflammatory bowel disease based on the national growth reference. Arab J Gastroenterol 2020;21:179-82. [PMID: 32798189 DOI: 10.1016/j.ajg.2020.07.002] [Reference Citation Analysis]
177 Guo D, Yang J, Ling F, Tu L, Li J, Chen Y, Zou K, Zhu L, Hou X. Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis. J Immunol Res 2020;2020:9430763. [PMID: 32855978 DOI: 10.1155/2020/9430763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
178 Batra SK, Heier CR, Diaz-Calderon L, Tully CB, Fiorillo AA, van den Anker J, Conklin LS. Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1597-606. [PMID: 32793975 DOI: 10.1093/ibd/izaa209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
179 Martin NG, Roberts AJ, Evans HM, Bishop J, Day AS. Three-year outcomes of childhood inflammatory bowel disease in New Zealand: A population-based cohort study. JGH Open 2020;4:642-8. [PMID: 32782951 DOI: 10.1002/jgh3.12310] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
180 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
181 Xie Y, Li D, Luan X, Jin S, Yan B, Tian F. Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells. Can J Gastroenterol Hepatol 2020;2020:8861854. [PMID: 32766176 DOI: 10.1155/2020/8861854] [Reference Citation Analysis]
182 Dipasquale V, Romano C. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety. J Clin Pharm Ther 2020;45:1228-34. [PMID: 32743840 DOI: 10.1111/jcpt.13239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
183 Scarpato E, Strisciuglio C, Martinelli M, Russo M, Cenni S, Casertano M, Serra MR, Staiano A, Miele E. Exclusive enteral nutrition effect on the clinical course of pediatric Crohn's disease: a single center experience. Eur J Pediatr 2020;179:1925-34. [PMID: 32734315 DOI: 10.1007/s00431-020-03753-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
184 Yamamoto T, Lightner AL, Spinelli A, Kotze PG. Perioperative management of ileocecal Crohn's disease in the current era. Expert Rev Gastroenterol Hepatol 2020;14:843-55. [PMID: 32729736 DOI: 10.1080/17474124.2020.1802245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Agrawal G, Hamblin H, Clancy A, Borody T. Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn's Disease. Microorganisms. 2020;8:1112. [PMID: 32722117 DOI: 10.3390/microorganisms8081112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
186 Levine A, Chanchlani N, Hussey S, Ziv-Baran T, Escher JC, Amil Dias J, Veres G, Koletzko S, Turner D, Kolho KL, Paerregaard A, Staiano A, Lionetti P, Nuti F, Sladek M, Shaoul R, Lazowska-Prezeorek I, Martin de Carpi J, Sigall Boneh R, Pfeffer Gik T, Cohen-Dolev N, Russell RK. Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn's Disease: Results From the Porto Group GROWTH Study. J Crohns Colitis 2020;14:71-8. [PMID: 31162532 DOI: 10.1093/ecco-jcc/jjz111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
187 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignaß A, Kucharzik T; Collaborators:. [Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers]. Z Gastroenterol 2020;58:672-92. [PMID: 32659830 DOI: 10.1055/a-1193-5475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
188 Gkikas K, Gerasimidis K, Milling S, Ijaz UZ, Hansen R, Russell RK. Dietary Strategies for Maintenance of Clinical Remission in Inflammatory Bowel Diseases: Are We There Yet? Nutrients 2020;12:E2018. [PMID: 32645980 DOI: 10.3390/nu12072018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
189 Tang W, Huang Y, Shi P, Wang Y, Zhang Y, Xue A, Tang Z, Hu W, Sun H, Zhang P, Zheng C, Shi J, Wang S, Qiu X, Lu X, Miao S, Meng Y. Effect of Exclusive Enteral Nutrition on the Disease Process, Nutrition Status, and Gastrointestinal Microbiota for Chinese Children With Crohn's Disease. JPEN J Parenter Enteral Nutr 2021;45:826-38. [PMID: 32510616 DOI: 10.1002/jpen.1938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
190 Harris RE, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Turner D, Veereman G, Neyt M, Bigot L, Ruemmele FM, Russell RK; PIBD SETQuality consortium and PIBDnet. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. BMJ Open 2020;10:e034892. [PMID: 32611737 DOI: 10.1136/bmjopen-2019-034892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
191 Choe YH. Precision medicine for pediatric inflammatory bowel disease: a perspective. Precis Future Med 2020;4:43-52. [DOI: 10.23838/pfm.2020.00058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Kang B, Kim TJ, Choi J, Baek SY, Ahn S, Choi R, Lee SY, Choe YH. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers. Aliment Pharmacol Ther 2020;52:459-70. [PMID: 32598049 DOI: 10.1111/apt.15810] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
193 Saadah OI, Annese V, Mosli MH. Prevalence and Predictors of Reduced Bone Density in Child and Adolescent Patients With Crohn's Disease. J Clin Densitom 2021;24:252-8. [PMID: 32553268 DOI: 10.1016/j.jocd.2020.05.004] [Reference Citation Analysis]
194 Costa-Santos MP, Palmela C, Torres J, Ferreira A, Velho S, Ourô S, Glória L, Gordo I, Maio R, Cravo M. Preoperative enteral nutrition in adults with complicated Crohn's disease: Effect on disease outcomes and gut microbiota. Nutrition 2020;70S:100009. [PMID: 34301372 DOI: 10.1016/j.nutx.2020.100009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
195 Appleton L, Watt E, Jagger F, Hansen R, Gearry RB, Day AS. Associations between the Presence of Granulomata and Disease Phenotype and Outcomes in Children Diagnosed with Crohn’s Disease. GastrointestDisord 2020;2:164-70. [DOI: 10.3390/gidisord2020017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Hart L, Farbod Y, Szamosi JC, Yamamoto M, Britz-McKibbin P, Halgren C, Zachos M, Pai N. Effect of Exclusive Enteral Nutrition and Corticosteroid Induction Therapy on the Gut Microbiota of Pediatric Patients with Inflammatory Bowel Disease. Nutrients 2020;12:E1691. [PMID: 32517036 DOI: 10.3390/nu12061691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
197 Adler J, Lin CC, Gadepalli SK, Dombkowski KJ. Association Between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications Among Young Patients With Crohn Disease. JAMA Netw Open. 2020;3:e207378. [PMID: 32515798 DOI: 10.1001/jamanetworkopen.2020.7378] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
198 Strisciuglio C, Scarpato E, Cenni S, Serra M, Giugliano F, Mainolfi C, Dolce P, Martinelli M, Staiano A, Miele E. Improvement of body composition and bone mineral density after enteral nutrition in pediatric Crohn disease. Digestive and Liver Disease 2020;52:630-6. [DOI: 10.1016/j.dld.2020.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Ashton JJ, Green Z, Beattie RM. Beyond bedside measures of malnutrition in paediatric Crohn's disease – Should we be thinking of sarcopenia. Clinical Nutrition 2020;39:1639-42. [DOI: 10.1016/j.clnu.2020.03.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Stawowczyk E, Kawalec P, Kowalska-Duplaga K, Mossakowska M. Productivity Loss Among Parents of Children With Inflammatory Bowel Diseases in Relation to Disease Activity and Patient's Quality of Life. J Pediatr Gastroenterol Nutr 2020;71:340-5. [PMID: 32459743 DOI: 10.1097/MPG.0000000000002801] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
201 Sharma S, Gupta A, Kedia S, Agarwal S, Singh N, Goyal S, Jain S, Gupta V, Sahu P, Vuyyuru SK, Kante B, Sharma R, Panwar R, Sahni P, Makharia G, Ahuja V. Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn's disease. Intest Res 2021;19:291-300. [PMID: 32447877 DOI: 10.5217/ir.2019.09172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
202 Bae J, Choe BH, Kang B. Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn's disease who turned out to possess homozygous mutations in NUDT15 R139C. Yeungnam Univ J Med 2020;37:332-6. [PMID: 32438538 DOI: 10.12701/yujm.2020.00178] [Reference Citation Analysis]
203 Pascual Pérez AI, Pujol Muncunill G, Domínguez Sánchez P, Feo Ortega S, Martín de Carpi J. [Duration of sustained remission after treatment by induction with exclusive enteral nutrition and azathioprine in patients with Crohn's disease]. An Pediatr (Engl Ed) 2021;94:252-3. [PMID: 32430216 DOI: 10.1016/j.anpedi.2020.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
205 Sandberg K, Yarger E, Saeed S. Updates in diagnosis and management of inflammatory bowel disease.Curr Probl Pediatr Adolesc Health Care. 2020;50:100785. [PMID: 32402535 DOI: 10.1016/j.cppeds.2020.100785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
206 Colquhoun C, Duncan M, Grant G. Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbiosis. Diseases 2020;8:E13. [PMID: 32397606 DOI: 10.3390/diseases8020013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
207 Silva LC, Seixas RBPM, de Carvalho E. Quality of Life in Children and Adolescents with Inflammatory Bowel Disease: Impact and Predictive Factors. Pediatr Gastroenterol Hepatol Nutr 2020;23:286-96. [PMID: 32483550 DOI: 10.5223/pghn.2020.23.3.286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
208 Peter I, Maldonado-Contreras A, Eisele C, Frisard C, Simpson S, Nair N, Rendon A, Hawkins K, Cawley C, Debebe A, Tarassishin L, White S, Dubinsky M, Stone J, Clemente JC, Sabino J, Torres J, Hu J, Colombel JF, Olendzki B. A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design. Contemp Clin Trials Commun 2020;18:100573. [PMID: 32617430 DOI: 10.1016/j.conctc.2020.100573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
209 Nardone OM, Iacucci M, Ghosh S, Castiglione F. Can a transition clinic bridge the gap between paediatric and adult inflammatory bowel disease care models? Digestive and Liver Disease 2020;52:516-27. [DOI: 10.1016/j.dld.2020.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
210 Levy-Shraga Y, Shenkar A, Modan-Moses D, Assa A, Haberman Y, Shouval D, Guz-Mark A, Lahad A, Weiss B. Longitudinal changes in bone mineral density in children with inflammatory bowel diseases. Acta Paediatr 2020;109:1026-32. [PMID: 31594031 DOI: 10.1111/apa.15046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
211 Choi SY, Choi YO, Choe YH, Kang B. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients. J Korean Med Sci 2020;35:e114. [PMID: 32329259 DOI: 10.3346/jkms.2020.35.e114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
212 Brückner A, Werkstetter KJ, Frivolt K, Shokry E, Ahmed M, Metwaly A, Marques JG, Uhl O, Krohn K, Hajji M, Otte S, Pozza SB, Bufler P, Liptay S, Haller D, Koletzko B, Koletzko S, Schwerd T. Partial enteral nutrition has no benefit on bone health but improves growth in paediatric patients with quiescent or mild Crohn's disease. Clin Nutr 2020;39:3786-96. [PMID: 32376096 DOI: 10.1016/j.clnu.2020.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
213 Dipasquale V, Tropeano A, Caime F, Romano C. Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. J Clin Pharm Ther 2020;45:819-21. [PMID: 32298484 DOI: 10.1111/jcpt.13140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Sigall Boneh R, Van Limbergen J, Wine E, Assa A, Shaoul R, Milman P, Cohen S, Kori M, Peleg S, On A, Shamaly H, Abramas L, Levine A. Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease. Clin Gastroenterol Hepatol 2021;19:752-9. [PMID: 32302709 DOI: 10.1016/j.cgh.2020.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
215 Wicker C, Roda C, Perry A, Arnoux JB, Brassier A, Castelle M, Servais A, Donadieu J, Bouchereau J, Pigneur B, Labrune P, Ruemmele FM, de Lonlay P. Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Mol Genet Metab Rep. 2020;23:100581. [PMID: 32300528 DOI: 10.1016/j.ymgmr.2020.100581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
216 Moriczi M, Pujol-Muncunill G, Martín-Masot R, Jiménez Treviño S, Segarra Cantón O, Ochoa Sangrador C, Peña Quintana L, González Santana D, Rodríguez Martínez A, Rosell Camps A, Armas H, Barrio J, González de Caldas R, Rodríguez Salas M, Balmaseda Serrano E, Donat Aliaga E, Bodas Pinedo A, Vaquero Sosa E, Vecino López R, Solar Boga A, Moreno Álvarez A, Sánchez Sánchez C, Tolín Hernani M, Gutiérrez Junquera C, Martinón Torres N, Leis Trabazo MR, Eizaguirre FJ, García Peris M, Medina Benítez E, Fernández Caamaño B, Vegas Álvarez AM, Crespo Valderrábano L, Alonso Vicente C, Rubio Santiago J, Galera-Martínez R, García-Romero R, Ros Arnal I, Fernández Cebrián S, Lorenzo Garrido H, Viada Bris JF, Velasco Rodríguez-Belvis M, Bartolomé Porro JM, Blanco Rodríguez M, Barros García P, Botija G, Chicano Marín FJ, La Orden Izquierdo E, Crehuá-Gaudiza E, Navas-López VM, Martín-de-Carpi J. Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP. Nutrients 2020;12:E1012. [PMID: 32272604 DOI: 10.3390/nu12041012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
217 Logan M, Gkikas K, Svolos V, Nichols B, Milling S, Gaya DR, Seenan JP, Macdonald J, Hansen R, Ijaz UZ, Russell RK, Gerasimidis K. Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease-new insights into dietary disease triggers. Aliment Pharmacol Ther 2020;51:935-47. [PMID: 32249975 DOI: 10.1111/apt.15695] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
218 Coelho T, Mossotto E, Gao Y, Haggarty R, Ashton JJ, Batra A, Stafford IS, Beattie RM, Williams AP, Ennis S. Immunological Profiling of Paediatric Inflammatory Bowel Disease Using Unsupervised Machine Learning. Journal of Pediatric Gastroenterology & Nutrition 2020;70:833-40. [DOI: 10.1097/mpg.0000000000002719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
219 Nikkonen A, Kolho KL. Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatr 2020;109:836-41. [PMID: 31535405 DOI: 10.1111/apa.15026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
220 Romeo AC, Ventimiglia M, Dipasquale V, Orlando A, Citrano M, Pellegrino S, Accomando S, Cottone M, Romano C. Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. Clinics and Research in Hepatology and Gastroenterology 2020;44:223-9. [DOI: 10.1016/j.clinre.2019.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
221 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
222 Wilson DC, Griffiths AM. Thiopurine Monotherapy in Paediatric Inflammatory Bowel Disease: 20 Years After Markowitz. Journal of Pediatric Gastroenterology & Nutrition 2020;70:758-9. [DOI: 10.1097/mpg.0000000000002697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Kowalska-Duplaga K, Kapusta P, Gosiewski T, Sroka-Oleksiak A, Ludwig-Słomczyńska AH, Wołkow PP, Fyderek K. Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn's Disease. J Clin Med 2020;9:E687. [PMID: 32143438 DOI: 10.3390/jcm9030687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
224 van Rheenen H, van Rheenen PF. Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121-31. [PMID: 32206624 DOI: 10.5223/pghn.2020.23.2.121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
225 Selinger CP, Ochieng AO, George V, Leong RW. The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios. Inflamm Bowel Dis 2019;25:919-24. [PMID: 30265299 DOI: 10.1093/ibd/izy309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
226 Courbette O, Aupiais C, Viala J, Hugot J, Roblin X, Candon S, Louveau B, Chatenoud L, Martinez-vinson C. Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology & Nutrition 2020;70:310-7. [DOI: 10.1097/mpg.0000000000002536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
227 Krzesiek E, Nienartowicz E, Iwańczak B. Value of magnetic resonance enterography in diagnosis and treatment follow up in Crohn's disease in children. Adv Med Sci 2020;65:214-22. [PMID: 32087571 DOI: 10.1016/j.advms.2020.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
228 Atia O, Ledder O, Ben-moshe T, Lev-tzion R, Rachmen Y, Meyer EO, Beeri R, Renbaum P, Shamasneh I, Shteyer E, Turner D. Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study. Journal of Pediatric Gastroenterology & Nutrition 2020;70:825-32. [DOI: 10.1097/mpg.0000000000002566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
229 Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V, Gupta YK, Kaur K. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020;18:184-91. [PMID: 32092799 DOI: 10.5217/ir.2019.00094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
230 Choi SY, Kang B, Choe YH. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease. Gut Liver 2019;13:541-8. [PMID: 30970435 DOI: 10.5009/gnl18129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
231 Larisia M, Eugen D, Irina P, Tatiana C, Adina U, Sergiu C, Cristina M, Adriana B. Challenges in Pediatric Inflammatory Bowel Disease. ARS Medica Tomitana 2019;25:132-7. [DOI: 10.2478/arsm-2019-0027] [Reference Citation Analysis]
232 Ashton JJ, Borca F, Mossotto E, Phan HTT, Ennis S, Beattie RM. Analysis and Hierarchical Clustering of Blood Results Before Diagnosis in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:469-75. [PMID: 30561629 DOI: 10.1093/ibd/izy369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
233 Park S, Kang Y, Koh H, Kim S. Increasing incidence of inflammatory bowel disease in children and adolescents: significance of environmental factors. Clin Exp Pediatr 2020;63:337-44. [PMID: 32024322 DOI: 10.3345/cep.2019.00500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
234 Chuong KH, Haw J, Stintzi A, Mack DR, O'Doherty KC. Dietary strategies and food practices of pediatric patients, and their parents, living with inflammatory bowel disease: a qualitative interview study. Int J Qual Stud Health Well-being 2019;14:1648945. [PMID: 31382870 DOI: 10.1080/17482631.2019.1648945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
235 Däbritz J. Besonderheiten der Therapie chronisch-entzündlicher Darmerkrankungen im Kindes- und Jugendalter. Monatsschr Kinderheilkd 2020;168:344-51. [DOI: 10.1007/s00112-020-00855-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, Walters TD, Griffiths AM. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis. J Crohns Colitis 2019;13:982-9. [PMID: 30715240 DOI: 10.1093/ecco-jcc/jjz019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
237 Pellino G, Keller DS, Sampietro GM, Annese V, Carvello M, Celentano V, Coco C, Colombo F, Cracco N, Di Candido F, Franceschi M, Laureti S, Mattioli G, Pio L, Sciaudone G, Sica G, Villanacci V, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F;  the Italian Society of Colorectal Surgery (SICCR). Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. Tech Coloproctol. 2020;24:105-126. [PMID: 31983044 DOI: 10.1007/s10151-019-02145-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
238 Pigneur B, Lepage P, Mondot S, Schmitz J, Goulet O, Doré J, Ruemmele FM. Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children With Crohn's Disease. J Crohns Colitis 2019;13:846-55. [PMID: 30541015 DOI: 10.1093/ecco-jcc/jjy207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
239 Bischoff SC, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Forbes A. ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clin Nutr 2020;39:632-53. [PMID: 32029281 DOI: 10.1016/j.clnu.2019.11.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 84] [Article Influence: 22.0] [Reference Citation Analysis]
240 Duricova D, Sarter H, Savoye G, Leroyer A, Pariente B, Armengol-Debeir L, Bouguen G, Ley D, Turck D, Templier C, Buche S, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M; Epimad Group. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. Inflamm Bowel Dis 2019;25:394-402. [PMID: 30085159 DOI: 10.1093/ibd/izy254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
241 Weintraub Y, Cohen S, Chapnik N, Ben-tov A, Yerushalmy-feler A, Dotan I, Tauman R, Froy O. Clock Gene Disruption Is an Initial Manifestation of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2020;18:115-122.e1. [DOI: 10.1016/j.cgh.2019.04.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
242 Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut 2020;69:32-41. [PMID: 30979718 DOI: 10.1136/gutjnl-2018-317987] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
243 Ludvigsson JF, Mahl M, Sachs MC, Björk J, Michaelsson K, Ekbom A, Askling J, Backman AS, Olén O. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014. Am J Gastroenterol 2019;114:291-304. [PMID: 30730858 DOI: 10.14309/ajg.0000000000000062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
244 McVeigh L, Payne A. Inducing remission in paediatric Crohn's disease using nutritional therapies - A systematic review. J Hum Nutr Diet 2020;33:170-86. [PMID: 31797471 DOI: 10.1111/jhn.12714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
245 Connors J, Dunn KA, Allott J, Bandsma R, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. The relationship between fecal bile acids and microbiome community structure in pediatric Crohn's disease. ISME J 2020;14:702-13. [PMID: 31796936 DOI: 10.1038/s41396-019-0560-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
246 Urlep D, Benedik E, Brecelj J, Orel R. Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study. Eur J Pediatr 2020;179:431-8. [PMID: 31781933 DOI: 10.1007/s00431-019-03520-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
247 Pigneur B, Ruemmele FM. Nutritional interventions for the treatment of IBD: current evidence and controversies. Therap Adv Gastroenterol 2019;12:1756284819890534. [PMID: 31803252 DOI: 10.1177/1756284819890534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
248 Takeuchi I, Kaburaki Y, Arai K, Shimizu H, Hirano Y, Nagata S, Shimizu T. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan. J Gastroenterol Hepatol 2020;35:593-600. [PMID: 31425641 DOI: 10.1111/jgh.14836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
249 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
250 Shaoul R, Day AS. Nutritional regulators of intestinal inflammation. Current Opinion in Gastroenterology 2019;35:486-90. [DOI: 10.1097/mog.0000000000000585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
251 Whited T, Berber A. A 17-Year-Old Male With Abdominal Pain in Primary Care. The Journal for Nurse Practitioners 2019;15:e201-4. [DOI: 10.1016/j.nurpra.2019.04.012] [Reference Citation Analysis]
252 Ruemmele FM. Safety of anti-TNF biologics in paediatric inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2019;4:813-5. [DOI: 10.1016/s2468-1253(19)30292-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
253 Sokollik C, Fournier N, Rizzuti D, Braegger CP, Nydegger A, Schibli S, Spalinger J; Swiss IBD Cohort Study Group. The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease. J Clin Gastroenterol 2018;52:e87-91. [PMID: 28644308 DOI: 10.1097/MCG.0000000000000864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
254 Malham M, Jakobsen C, Vester‐andersen MK, Lo B, Paerregaard A, Vind I, Wewer V. Paediatric onset inflammatory bowel disease is a distinct and aggressive phenotype—a comparative population‐based study. GastroHep 2019;1:266-73. [DOI: 10.1002/ygh2.368] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
255 Ashton JJ, Green Z, Kolimarala V, Beattie RM. Inflammatory bowel disease: long-term therapeutic challenges. Expert Rev Gastroenterol Hepatol 2019;13:1049-63. [PMID: 31657969 DOI: 10.1080/17474124.2019.1685872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
256 Yoon JY. Nutritional approach as therapeutic manipulation in inflammatory bowel disease. Intest Res 2019;17:463-75. [PMID: 31665832 DOI: 10.5217/ir.2019.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
257 Scarpato E, Russo M, Staiano A. Probiotics in Pediatric Gastroenterology: Emerging Indications: Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S7-9. [PMID: 30036240 DOI: 10.1097/MCG.0000000000001095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
258 Hirai F, Takeda T, Takada Y, Kishi M, Beppu T, Takatsu N, Miyaoka M, Hisabe T, Yao K, Ueki T. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. J Gastroenterol 2020;55:133-41. [PMID: 31641874 DOI: 10.1007/s00535-019-01634-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
259 Yerushalmy-Feler A, Assa A. Pharmacological Prevention and Management of Postoperative Relapse in Pediatric Crohn's Disease. Paediatr Drugs 2019;21:451-60. [PMID: 31628665 DOI: 10.1007/s40272-019-00361-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
260 van Hoeve K, Hoffman I, D'Hoore A, Ferrante M, Vermeire S. Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. Dig Liver Dis 2020;52:164-72. [PMID: 31640916 DOI: 10.1016/j.dld.2019.09.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
261 Grover Z, Alex G. Management of inflammatory bowel disease in children: It is time for an individualised approach. J Paediatr Child Health 2020;56:1677-84. [DOI: 10.1111/jpc.14652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, Gu G, Wang G, Wang Z, Wu X, Ren J. Preliminary exploration of the potential of spliceosome‐associated protein 130 for predicting disease severity in Crohn's disease. Ann N Y Acad Sci 2019;1462:128-38. [DOI: 10.1111/nyas.14240] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
263 Zimmerman L, Bousvaros A. The pharmacotherapeutic management of pediatric Crohn's disease. Expert Opin Pharmacother. 2019;20:2161-2168. [PMID: 31574236 DOI: 10.1080/14656566.2019.1659778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 Hradsky O, Potuznikova K, Siroka J, Lerchova T, Urbanek L, Mihal V, Spenerova M, Velganova-veghova M, Karaskova E, Bronsky J. Prediction of Thiopurine Metabolite Levels Based on Haematological and Biochemical Parameters. Journal of Pediatric Gastroenterology & Nutrition 2019;69:e105-10. [DOI: 10.1097/mpg.0000000000002436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
265 Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2019;69:474-9. [DOI: 10.1097/mpg.0000000000002410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
266 Agin M, Yucel A, Gumus M, Yuksekkaya HA, Tumgor G. The Effect of Enteral Nutrition Support Rich in TGF-β in the Treatment of Inflammatory Bowel Disease in Childhood. Medicina (Kaunas) 2019;55:E620. [PMID: 31546703 DOI: 10.3390/medicina55100620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
267 Di Caro S, Fragkos KC, Keetarut K, Koo HF, Sebepos-Rogers G, Saravanapavan H, Barragry J, Rogers J, Mehta SJ, Rahman F. Enteral Nutrition in Adult Crohn's Disease: Toward a Paradigm Shift. Nutrients 2019;11:E2222. [PMID: 31540038 DOI: 10.3390/nu11092222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
268 Lauritzen D, Andreassen BU, Heegaard NHH, Klinge LG, Walsted AM, Neland M, Nielsen RG, Wittenhagen P. Pediatric Inflammatory Bowel Diseases: Should We Be Looking for Kidney Abnormalities? Inflamm Bowel Dis 2018;24:2599-605. [PMID: 29718370 DOI: 10.1093/ibd/izy166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
269 Day A, Wood J, Melton S, Bryant RV. Exclusive enteral nutrition: An optimal care pathway for use in adult patients with active Crohn's disease. JGH Open 2020;4:260-6. [PMID: 32280775 DOI: 10.1002/jgh3.12256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
270 Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, Halfvarson J, Hjortswang H, Jäghult S, Karling P, Nordenvall C, Olén O, Olsson M, Rejler M, Strid H, Myrelid P. Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. Scand J Gastroenterol 2019;54:1089-101. [PMID: 31498717 DOI: 10.1080/00365521.2019.1660799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
271 Wang S, Martins R, Sullivan MC, Friedman ES, Misic AM, El-Fahmawi A, De Martinis ECP, O'Brien K, Chen Y, Bradley C, Zhang G, Berry ASF, Hunter CA, Baldassano RN, Rondeau MP, Beiting DP. Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids. Microbiome. 2019;7:126. [PMID: 31472697 DOI: 10.1186/s40168-019-0740-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
272 Harris RE, Sim W, Sutton H, Garrick V, Curtis L, Gervais L, Merrick V, Barclay AR, Flynn DM, Tayler R, Hansen R, Russell RK. Using a Steroid-sparing Tool in Paediatric Inflammatory Bowel Disease to Evaluate Steroid Use and Dependency. J Pediatr Gastroenterol Nutr 2019;69:557-63. [PMID: 31436708 DOI: 10.1097/MPG.0000000000002442] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
273 Veenbergen S, Li P, Raatgeep HC, Lindenbergh-Kortleve DJ, Simons-Oosterhuis Y, Farrel A, Costes LMM, Joosse ME, van Berkel LA, de Ruiter LF, van Leeuwen MA, Winter D, Holland SM, Freeman AF, Wakabayashi Y, Zhu J, de Ridder L, Driessen GJ, Escher JC, Leonard WJ, Samsom JN. IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4+ T cells: relevance to inflammatory bowel disease. Mucosal Immunol 2019;12:1201-11. [PMID: 31417161 DOI: 10.1038/s41385-019-0194-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
274 Sharma Y, Bousvaros A, Liu E, Bender Stern J. Natural history of children with mild Crohn’s disease. World J Gastroenterol 2019; 25(30): 4235-4245 [PMID: 31435176 DOI: 10.3748/wjg.v25.i30.4235] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
275 Prendaj E, Thomas S, Tomer G. Population Management: A Tool to Improve Timely Care in Pediatric and Young Adult Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2019;2019:4702969. [PMID: 31396273 DOI: 10.1155/2019/4702969] [Reference Citation Analysis]
276 Frivolt K, Schwerd T, Schatz SB, Freudenberg F, Prell C, Werkstetter KJ, Bufler P, Koletzko S. Hyperadiponectinemia During Infliximab Induction Therapy in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2018;66:915-9. [PMID: 29287006 DOI: 10.1097/MPG.0000000000001876] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
277 Piekkala M, Alfthan H, Merras-Salmio L, Puustinen Wikström A, Heiskanen K, Jaakkola T, Klemetti P, Färkkilä M, Kolho KL. Fecal Calprotectin Test Performed at Home: A Prospective Study of Pediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2018;66:926-31. [PMID: 29240011 DOI: 10.1097/MPG.0000000000001861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
278 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology 2019;157:320-48. [DOI: 10.1053/j.gastro.2019.03.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
279 Wang X, Wang G, Shang J, Pan H, Zhang XA, Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res 2019;47:3534-49. [PMID: 31364448 DOI: 10.1177/0300060519864800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Strisciuglio C, Bellini G, Miele E, Martinelli M, Cenni S, Tortora C, Tolone C, Miraglia Del Giudice E, Rossi F. Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease. J Clin Gastroenterol. 2018;52:e37-e43. [PMID: 27875353 DOI: 10.1097/mcg.0000000000000755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
281 Logan M, Clark CM, Ijaz UZ, Gervais L, Duncan H, Garrick V, Curtis L, Buchanan E, Cardigan T, Armstrong L, Delahunty C, Flynn DM, Barclay AR, Tayler R, McDonald E, Milling S, Hansen RK, Gerasimidis K, Russell RK. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Aliment Pharmacol Ther 2019;50:664-74. [PMID: 31342536 DOI: 10.1111/apt.15425] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
282 Woo MH, Cho YH, Sohn MJ, Lee EJ, Kim JW, Moon JS, Ko JS, Kim HY. Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease. Pediatr Gastroenterol Hepatol Nutr 2019;22:358-68. [PMID: 31338311 DOI: 10.5223/pghn.2019.22.4.358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
283 Kaenkumchorn T, Kesavan A. Dietary Management of Pediatric Inflammatory Bowel Disease. J Med Food 2019;22:1092-9. [PMID: 31329006 DOI: 10.1089/jmf.2019.0063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
284 van Wassenaer EA, Meester VL, Kindermann A, Koot BGP, Benninga MA, de Meij TGJ. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study. Eur J Clin Pharmacol 2019;75:1445-50. [DOI: 10.1007/s00228-019-02715-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
285 Modrackova N, Bunesova V, Vlkova E, Musilova S, Mrvikova I, Bronsky J, Copova I, Hradsky O, Nevoral J. Enteral Nutrition as a Growth Medium for Cultivable Commensal Bacteria and Its Effect on Their Quantity in the Stool of Children with Crohn's Disease. J Med Food 2019;22:810-6. [PMID: 31313967 DOI: 10.1089/jmf.2019.0021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
286 Ledder O, Turner D. Antibiotics in IBD: Still a Role in the Biological Era? Inflamm Bowel Dis. 2018;24:1676-1688. [PMID: 29722812 DOI: 10.1093/ibd/izy067] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
287 Peng K, Qian X, Huang Z, Lu J, Wang Y, Zhou Y, Wang H, Wu B, Wang Y, Chen L, Zhai X, Huang Y. Umbilical Cord Blood Transplantation Corrects Very Early-Onset Inflammatory Bowel Disease in Chinese Patients With IL10RA-Associated Immune Deficiency. Inflamm Bowel Dis 2018;24:1416-27. [PMID: 29788474 DOI: 10.1093/ibd/izy028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
288 Silva F, Gatica T, Pavez C. ETIOLOGÍA Y FISIOPATOLOGÍA DE LA ENFERMEDAD INFLAMATORIA INTESTINAL. Revista Médica Clínica Las Condes 2019;30:262-72. [DOI: 10.1016/j.rmclc.2019.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
289 Castro F, de Souza HSP. Dietary Composition and Effects in Inflammatory Bowel Disease. Nutrients 2019;11:E1398. [PMID: 31234325 DOI: 10.3390/nu11061398] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
290 Wasielewska Z, Dolińska A, Wilczyńska D, Szaflarska-Popławska A, Krogulska A. Prevalence of allergic diseases in children with inflammatory bowel disease. Postepy Dermatol Alergol 2019;36:282-90. [PMID: 31333345 DOI: 10.5114/ada.2018.81189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
291 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
292 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
293 Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019;157:440-450. [PMID: 31170412 DOI: 10.1053/j.gastro.2019.04.021] [Cited by in Crossref: 135] [Cited by in F6Publishing: 190] [Article Influence: 45.0] [Reference Citation Analysis]
294 van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 2019;41:317-24. [DOI: 10.1097/ftd.0000000000000601] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
295 Kowalska-Duplaga K, Krawczyk A, Sroka-Oleksiak A, Salamon D, Wędrychowicz A, Fyderek K, Gosiewski T. Dependence of Colonization of the Large Intestine by Candida on the Treatment of Crohn's Disease. Pol J Microbiol 2019;68:121-6. [PMID: 31050260 DOI: 10.21307/pjm-2019-014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
296 Molendijk I, van der Marel S, Maljaars PWJ. Towards a Food Pharmacy: Immunologic Modulation through Diet. Nutrients 2019;11:E1239. [PMID: 31159179 DOI: 10.3390/nu11061239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
297 Sochet AA, Son S, Ryan KS, Roddy M, Barrie E, Wilsey M, McKinley SD, Nakagawa TA. Stress ulcer prophylaxis in children with status asthmaticus receiving systemic corticosteroids: a descriptive study assessing frequency of clinically important bleeding. J Asthma 2020;57:858-65. [PMID: 31046509 DOI: 10.1080/02770903.2019.1614617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
298 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2019;13:189-197. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
299 Turner D. Particularities of IBD Trials in Children. CPD 2019;25:69-72. [DOI: 10.2174/1381612825666190307125511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
300 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
301 He C, Wang H, Liao WD, Peng C, Shu X, Zhu X, Zhu ZH. Characteristics of mucosa-associated gut microbiota during treatment in Crohn’s disease. World J Gastroenterol 2019; 25(18): 2204-2216 [PMID: 31143071 DOI: 10.3748/wjg.v25.i18.2204] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
302 Sáez-González E, Mateos B, López-Muñoz P, Iborra M, Moret I, Nos P, Beltrán B. Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease.Nutrients. 2019;11:1062. [PMID: 31083616 DOI: 10.3390/nu11051062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
303 Walker R, Kammermeier J, Vora R, Mutalib M. Azathioprine dosing and metabolite measurement in pediatric inflammatory bowel disease: does one size fit all? Ann Gastroenterol 2019;32:387-91. [PMID: 31263361 DOI: 10.20524/aog.2019.0381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Bronsky J, de Ridder L, Ruemmele FM, Griffiths A, Buderus S, Hradsky O, Hauer AC. Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey. Journal of Pediatric Gastroenterology & Nutrition 2019;68:676-83. [DOI: 10.1097/mpg.0000000000002233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
305 Hojsak I, Matic K, Sila S, Trivić I, Mišak Z, Kolaček S. Characteristics of polymeric formula and route of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in pediatric Crohn's disease. Clin Nutr 2020;39:1108-11. [PMID: 31031135 DOI: 10.1016/j.clnu.2019.04.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
306 Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, Dipasquale V, Paci M, Zuin G, Aloi M, Strisciuglio C, Miele E, Pastore M, Martelossi S, Alvisi P; SIGENP IBD Working Group. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterol J 2019;7:759-66. [PMID: 31316780 DOI: 10.1177/2050640619847592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
307 Barfield E, Sockolow R, Hoffenberg E, Saeed S, Kim S, Siebold L, Picoraro J, Moses J, Dykes D, Grossman A, Wahbeh G, Park KT. Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:680-6. [PMID: 29324477 DOI: 10.1097/MPG.0000000000001890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
308 Shaoul R, Brown S, Day AS. Reasoning Beyond the Potential Use of Exclusive Enteral Nutrition and Other Specified Diets in Children With Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2018;66:378-82. [PMID: 29036010 DOI: 10.1097/MPG.0000000000001785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
309 Ashton JJ, Bonduelle Q, Mossotto E, Coelho T, Batra A, Afzal NA, Vadgama B, Ennis S, Beattie RM. Endoscopic and Histological Assessment of Paediatric Inflammatory Bowel Disease Over a 3-Year Follow-up Period. J Pediatr Gastroenterol Nutr. 2018;66:402-409. [PMID: 28922257 DOI: 10.1097/mpg.0000000000001729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
310 Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:133-140.e1. [PMID: 30981008 DOI: 10.1016/j.cgh.2019.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
311 Damas OM, Garces L, Abreu MT. Diet as Adjunctive Treatment for Inflammatory Bowel Disease: Review and Update of the Latest Literature. Curr Treat Options Gastroenterol. 2019;17:313-325. [PMID: 30968340 DOI: 10.1007/s11938-019-00231-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
312 Brückner A, Werkstetter KJ, de Laffolie J, Wendt C, Prell C, Weidenhausen T, Zimmer KP, Koletzko S; CEDATA-GPGE study group. Incidence and Risk Factors for Perianal Disease in Pediatric Crohn Disease Patients Followed in CEDATA-GPGE Registry. J Pediatr Gastroenterol Nutr 2018;66:73-8. [PMID: 28604511 DOI: 10.1097/MPG.0000000000001649] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
313 Eloi C, Foulon G, Bridoux-henno L, Breton E, Pelatan C, Chaillou E, Grimal I, Darviot E, Carré E, Gastineau S, Tourtelier Y, Nicaise D, Rousseau C, Dabadie A. Inflammatory Bowel Diseases and School Absenteeism. Journal of Pediatric Gastroenterology & Nutrition 2019;68:541-6. [DOI: 10.1097/mpg.0000000000002207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
314 Bouchard D, Brochard C, Vinson-Bonnet B, Staumont G, Abramowitz L, Benfredj P, Fathallah N, Faucheron JL, Higuero T, Panis Y, de Parades V, Siproudhis L, Laharie D, Pigot F. How to manage anal ulcerations and anorectal stenosis in Crohn's disease: algorithm-based decision making : French National Working Group Consensus 2018. Tech Coloproctol 2019;23:353-60. [PMID: 30937646 DOI: 10.1007/s10151-019-01971-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
315 Dalzell AM, Ba’ath ME. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries. Paediatrics and International Child Health 2019;39:48-58. [DOI: 10.1080/20469047.2019.1575056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Kim SJ, Ratchford TL, Buchanan PM, Patel DR, Tao TY, Teckman JH, Brown JJ, Farmakis SG. Diagnostic accuracy of non-contrast magnetic resonance enterography in detecting active bowel inflammation in pediatric patients with diagnosed or suspected inflammatory bowel disease to determine necessity of gadolinium-based contrast agents. Pediatr Radiol 2019;49:759-69. [PMID: 30899973 DOI: 10.1007/s00247-019-04369-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
317 Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12:1249-1254. [PMID: 29939254 DOI: 10.1093/ecco-jcc/jjy087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
318 Rinawi F, Zevit N, Eliakim R, Niv Y, Shamir R, Assa A. Long-Term Outcomes After Primary Bowel Resection in Pediatric-Onset Crohn's Disease. Inflamm Bowel Dis 2017;24:149-58. [PMID: 29272491 DOI: 10.1093/ibd/izx030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
319 Bartels RH, Chimwezi E, Watson V, Pei L, Potani I, Allubha B, Chidzalo K, Wang D, Dube Q, Mallewa M, Allen A, Bandsma RHJ, Voskuijl WP, Allen SJ. Hypoallergenic and anti-inflammatory feeds in children with complicated severe acute malnutrition: an open randomised controlled 3-arm intervention trial in Malawi. Sci Rep 2019;9:2304. [PMID: 30783173 DOI: 10.1038/s41598-019-38690-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
320 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Finkel Y, Eberhardson M. Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease. Nutrients 2019;11:E414. [PMID: 30781421 DOI: 10.3390/nu11020414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
321 Chen JM, He LW, Yan T, Guo XF, Hu PJ, Peng JS, Cheng WJ, Li LL, He Q. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn's disease. Gastroenterol Rep (Oxf). 2019;7:176-184. [PMID: 31217981 DOI: 10.1093/gastro/goy050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
322 Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study. Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland. Eur J Gastroenterol Hepatol 2018;30:1159-67. [PMID: 29985208 DOI: 10.1097/MEG.0000000000001197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
323 Kang Y, Park S, Kim S, Kim SY, Koh H. Therapeutic Efficacy of Exclusive Enteral Nutrition with Specific Polymeric Diet in Pediatric Crohn's Disease. Pediatr Gastroenterol Hepatol Nutr 2019;22:72-9. [PMID: 30671376 DOI: 10.5223/pghn.2019.22.1.72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
324 Wintzell V, Svanström H, Olén O, Melbye M, Ludvigsson JF, Pasternak B. Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study. Lancet Child Adolesc Health 2019;3:158-65. [PMID: 30685366 DOI: 10.1016/S2352-4642(18)30401-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
325 Yu Y, Chen KC, Chen J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis. World J Pediatr. 2019;15:26-36. [PMID: 30666565 DOI: 10.1007/s12519-018-0204-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
326 Ferrara G, Petrillo MG, Giani T, Marrani E, Filippeschi C, Oranges T, Simonini G, Cimaz R. Clinical Use and Molecular Action of Corticosteroids in the Pediatric Age. Int J Mol Sci 2019;20:E444. [PMID: 30669566 DOI: 10.3390/ijms20020444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
327 Chaparro M, Garre A, Ricart E, Iglesias-Flores E, Taxonera C, Domènech E, Gisbert JP; ENEIDA study group. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther 2019;49:419-28. [PMID: 30637837 DOI: 10.1111/apt.15114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
328 Tarnok A, Kiss Z, Kadenczki O, Veres G. Characteristics of biological therapy in pediatric patients with Crohn's disease. Expert Opin Biol Ther 2019;19:181-96. [PMID: 30601083 DOI: 10.1080/14712598.2019.1564034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
329 Moon JS. Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases. Pediatr Gastroenterol Hepatol Nutr. 2019;22:50-56. [PMID: 30671373 DOI: 10.5223/pghn.2019.22.1.50] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
330 Kim J, Ye BD. Successful Transition from Pediatric to Adult Care in Inflammatory Bowel Disease: What is the Key? Pediatr Gastroenterol Hepatol Nutr 2019;22:28-40. [PMID: 30671371 DOI: 10.5223/pghn.2019.22.1.28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
331 Moon JS. Clinical aspects and treatments for pediatric inflammatory bowel disease. Intest Res 2019;17:17-23. [PMID: 30625263 DOI: 10.5217/ir.2018.00139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
332 Ashton JJ, Borca F, Mossotto E, Coelho T, Batra A, Afzal NA, Phan HTT, Stanton M, Ennis S, Beattie RM. Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther 2019;49:398-407. [PMID: 30628109 DOI: 10.1111/apt.15094] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
333 Basiaga ML, Ross ME, Gerber JS, Ogdie A. Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids. J Pediatric Infect Dis Soc 2018;7:283-9. [PMID: 28992298 DOI: 10.1093/jpids/pix052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
334 Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, Ravelli A, Knafelz D, Martelossi S, Guariso G, Accomando S, Zuin G, De Giacomo C, Balzani L, Gennari M, Aloi M; SIGENP IBD Working Group. Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. Biologics 2019;13:13-21. [PMID: 30655661 DOI: 10.2147/BTT.S183088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
335 Bouchard D, Pigot F, Staumont G, Siproudhis L, Abramowitz L, Benfredj P, Brochard C, Fathallah N, Faucheron JL, Higuero T, Panis Y, de Parades V, Vinson-Bonnet B, Laharie D. Management of anoperineal lesions in Crohn's disease: a French National Society of Coloproctology national consensus. Tech Coloproctol 2018;22:905-17. [PMID: 30604249 DOI: 10.1007/s10151-018-1906-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
336 Krishnakumar C, Ballengee CR, Liu C, Kim M, Baker SS, Baldassano RN, Cohen SA, Crandall WV, Denson LA, Dubinsky MC, Evans J, Gokhale R, Griffiths A, Guthery SL, Oliva-hemker M, Heyman MB, Keljo D, Kellermayer R, Leleiko NS, Mack DR, Markowitz JF, Moulton DE, Noe JD, Otley AR, Patel AS, Pfefferkorn M, Rabizadeh S, Rosh JR, Snapper S, Walters TD, Ziring D, Mondal K, Kappelman MD, Hyams JS, Kugathasan S. Variation in Care in the Management of Children With Crohn’s Disease: Data From a Multicenter Inception Cohort Study. Inflammatory Bowel Diseases 2019;25:1208-17. [DOI: 10.1093/ibd/izy363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
337 O’morain N, O’morain C. The burden of digestive disease across Europe: Facts and policies. Digestive and Liver Disease 2019;51:1-3. [DOI: 10.1016/j.dld.2018.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
338 Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study. Journal of Pediatric Gastroenterology & Nutrition 2019;68:37-44. [DOI: 10.1097/mpg.0000000000002112] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
339 Ashton JJ, Mossotto E, Ennis S, Beattie RM. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr 2019;8:56-69. [PMID: 30881899 DOI: 10.21037/tp.2018.12.03] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
340 Grover Z. Predicting and preventing complications in children with inflammatory bowel disease. Transl Pediatr 2019;8:70-6. [PMID: 30881900 DOI: 10.21037/tp.2019.01.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
341 Ishige T. Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr 2019;8:16-22. [PMID: 30881894 DOI: 10.21037/tp.2018.12.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
342 Rocha A, Bessa I, Lago P, Santos MD, Leite J, Castro-Poças F. Preoperative Enteral Nutrition and Surgical Outcomes in Adults with Crohn's Disease: A Systematic Review. GE Port J Gastroenterol 2019;26:184-95. [PMID: 31192287 DOI: 10.1159/000494674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
343 Reddavide R, Rotolo O, Caruso MG, Stasi E, Notarnicola M, Miraglia C, Nouvenne A, Meschi T, De' Angelis GL, Di Mario F, Leandro G. The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. Acta Biomed 2018;89:60-75. [PMID: 30561397 DOI: 10.23750/abm.v89i9-S.7952] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
344 Ong C, Lim PT, Logarajah V, Liwanag MJ, Ang BX, Cher Y, Chiou FK, Kader A. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease. BMC Gastroenterol 2018;18:185. [PMID: 30541458 DOI: 10.1186/s12876-018-0907-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
345 Ho SSC, Day AS. Exclusive enteral nutrition in children with inflammatory bowel disease: Physician perspectives and practice. JGH Open 2019;3:148-53. [PMID: 31061890 DOI: 10.1002/jgh3.12121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
346 Svolos V, Hansen R, Nichols B, Quince C, Ijaz UZ, Papadopoulou RT, Edwards CA, Watson D, Alghamdi A, Brejnrod A, Ansalone C, Duncan H, Gervais L, Tayler R, Salmond J, Bolognini D, Klopfleisch R, Gaya DR, Milling S, Russell RK, Gerasimidis K. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology 2019;156:1354-1367.e6. [PMID: 30550821 DOI: 10.1053/j.gastro.2018.12.002] [Cited by in Crossref: 93] [Cited by in F6Publishing: 120] [Article Influence: 23.3] [Reference Citation Analysis]
347 Adamji M, Day AS. An overview of the role of exclusive enteral nutrition for complicated Crohn's disease. Intest Res 2019;17:171-6. [PMID: 30508476 DOI: 10.5217/ir.2018.00079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
348 Hyams JS, Dubinsky M, Rosh J, Ruemmele FM, Eichner SF, Maa JF, Lazar A, Alperovich G, Mostafa NM, Robinson AM. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis. Aliment Pharmacol Ther 2019;49:155-64. [PMID: 30506693 DOI: 10.1111/apt.15054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
349 Alghamdi A, Gerasimidis K, Blackburn G, Akinci D, Edwards C, Russell RK, Watson DG. Untargeted Metabolomics of Extracts from Faecal Samples Demonstrates Distinct Differences between Paediatric Crohn's Disease Patients and Healthy Controls but No Significant Changes Resulting from Exclusive Enteral Nutrition Treatment. Metabolites 2018;8:E82. [PMID: 30467282 DOI: 10.3390/metabo8040082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
350 Ziv-Baran T, Hussey S, Sladek M, Amil Dias J, Martin de Carpi J, Miele E, Veres G, Lionetti P, Koletzko S, Nuti F, Paerregaard A, Kolho KL, Russell RK, Shaoul R, Weiner D, Sigall Boneh R, Escher J, Finnby L, Turner D, Levine A. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease. Aliment Pharmacol Ther 2018;48:1242-50. [PMID: 30450578 DOI: 10.1111/apt.15016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
351 Kim J, Ye BD. Successful transition from pediatric to adult care in inflammatory bowel disease: what is the key? Intest Res 2019;17:24-35. [PMID: 30419636 DOI: 10.5217/ir.2018.00128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
352 Däbritz J, Gerner P, Enninger A, Claßen M, Radke M. Inflammatory Bowel Disease in Childhood and Adolescence. Dtsch Arztebl Int 2017;114:331-8. [PMID: 28597827 DOI: 10.3238/arztebl.2017.0331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
353 Capriati T, Bizzarri C, Dilillo A, Nobili V, Oliva S, Diamanti A. Growth failure in Crohn's disease children: may the first treatment have a role? Expert Rev Clin Immunol 2019;15:97-104. [PMID: 30403894 DOI: 10.1080/1744666X.2019.1543590] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
354 Choi J, Kang B, Kim MJ, Sohn I, Lee HJ, Choe YH. Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients. Gut Liver 2018;12:255-62. [PMID: 29298460 DOI: 10.5009/gnl17290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
355 Carroll MW, Kuenzig ME, Mack DR, Otley AR, Griffiths AM, Kaplan GG, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. J Can Assoc Gastroenterol 2019;2:S49-67. [PMID: 31294385 DOI: 10.1093/jcag/gwy056] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
356 Ashton JJ, Batra A, Beattie RM. Paediatric inflammatory bowel disease- brief update on current practice. Paediatrics and Child Health 2018;28:507-14. [DOI: 10.1016/j.paed.2018.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
357 Marrani E, Belli G, Simonini G, Trapani S, Caproni M, Lionetti P. SAPHO syndrome in pediatric patients with inflammatory bowel disease treated with infliximab. Digestive and Liver Disease 2018;50:1249-51. [DOI: 10.1016/j.dld.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
358 Serban ED. Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint? World J Clin Cases 2018; 6(12): 501-513 [PMID: 30397606 DOI: 10.12998/wjcc.v6.i12.501] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
359 Kim HA, Suh HR, Kang B, Choe BH; Crohn’s and Colitis Association in DaeguGyeongbuk (CCAiD). Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn's disease. Intest Res 2019;17:144-8. [PMID: 30317857 DOI: 10.5217/ir.2018.00104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
360 Brusaferro A, Cavalli E, Farinelli E, Cozzali R, Principi N, Esposito S. Gut dysbiosis and paediatric Crohn's disease. J Infect 2019;78:1-7. [PMID: 30336176 DOI: 10.1016/j.jinf.2018.10.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
361 Oliva S, Aloi M, Viola F, Mallardo S, Civitelli F, Maccioni F, Hassan C, Papoff P, Cucchiara S, Cohen SA. A Treat to Target Strategy Using Panenteric Capsule Endoscopy in Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2019;17:2060-2067.e1. [PMID: 30326301 DOI: 10.1016/j.cgh.2018.10.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
362 Ouldali N, Hugot JP, Viala J, Damir M, Martinez-Vinson C, Meinzer U. Early Arthritis Is Associated With Failure of Immunosuppressive Drugs and Severe Pediatric Crohn's Disease Evolution. Inflamm Bowel Dis 2018;24:2423-30. [PMID: 29788152 DOI: 10.1093/ibd/izy137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
363 Tran L, Mulligan K. A Systematic Review of Self-Management Interventions for Children and Adolescents With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:685-98. [DOI: 10.1093/ibd/izy299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
364 Wood P, Henderson P. Letter: screening for adrenal suppression in paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:884-5. [PMID: 30281831 DOI: 10.1111/apt.14861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
365 Uchiyama K, Kishi H, Komatsu W, Nagao M, Ohhira S, Kobashi G. Lipid and Bile Acid Dysmetabolism in Crohn's Disease. J Immunol Res 2018;2018:7270486. [PMID: 30402511 DOI: 10.1155/2018/7270486] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
366 Finlayson-trick E, Connors J, Stadnyk A, Van Limbergen J. Regulation of Antimicrobial Pathways by Endogenous Heat Shock Proteins in Gastrointestinal Disorders. GastrointestDisord 2018;1:39-56. [DOI: 10.3390/gidisord1010005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
367 Deneau MR, Mack C, Abdou R, Amin M, Amir A, Auth M, Bazerbachi F, Marie Broderick A, Chan A, DiGuglielmo M, El-Matary W, El-Youssef M, Ferrari F, Furuya KN, Gottrand F, Gupta N, Homan M, Jensen MK, Kamath BM, Mo Kim K, Kolho KL, Konidari A, Koot B, Iorio R, Martinez M, Mohan P, Palle S, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Valentino PL, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Miloh T. Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis. Hepatol Commun 2018;2:1369-78. [PMID: 30411083 DOI: 10.1002/hep4.1251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
368 Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2018;18:140. [PMID: 30219028 DOI: 10.1186/s12876-018-0868-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
369 Wang Y, Gao X, Ghozlane A, Hu H, Li X, Xiao Y, Li D, Yu G, Zhang T. Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy. J Crohns Colitis. 2018;12:337-346. [PMID: 29194468 DOI: 10.1093/ecco-jcc/jjx153] [Cited by in Crossref: 55] [Cited by in F6Publishing: 83] [Article Influence: 13.8] [Reference Citation Analysis]
370 Nordenvall C, Rosvall O, Bottai M, Everhov ÅH, Malmborg P, Smedby KE, Ekbom A, Askling J, Ludvigsson JF, Myrelid P, Olén O. Surgical Treatment in Childhood-onset Inflammatory Bowel Disease-A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014. J Crohns Colitis 2018;12:157-66. [PMID: 29029152 DOI: 10.1093/ecco-jcc/jjx132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
371 Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 2018;67:1726-38. [PMID: 29777041 DOI: 10.1136/gutjnl-2017-315866] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 35.8] [Reference Citation Analysis]
372 Copova I, Hradsky O, Zarubova K, Gonsorcikova L, Potuznikova K, Lerchova T, Nevoral J, Bronsky J. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease. Eur J Pediatr 2018;177:1685-93. [DOI: 10.1007/s00431-018-3228-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
373 Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS One 2018;13:e0201956. [PMID: 30114224 DOI: 10.1371/journal.pone.0201956] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
374 de Meij TGJ, de Groot EFJ, Peeters CFW, de Boer NKH, Kneepkens CMF, Eck A, Benninga MA, Savelkoul PHM, van Bodegraven AA, Budding AE. Variability of core microbiota in newly diagnosed treatment-naïve paediatric inflammatory bowel disease patients. PLoS One 2018;13:e0197649. [PMID: 30102706 DOI: 10.1371/journal.pone.0197649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
375 Lawley M, Wu JW, Navas-lópez VM, Huynh HQ, Carroll MW, Chen M, Medvedev P, Day AS, Hussey S, Sigall-boneh R, Levine A, Wine E. Global Variation in Use of Enteral Nutrition for Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2018;67:e22-9. [DOI: 10.1097/mpg.0000000000001946] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
376 Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci 2018;18:211-6. [PMID: 29338679 DOI: 10.17305/bjbms.2018.2792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
377 Sigall-Boneh R, Levine A, Lomer M, Wierdsma N, Allan P, Fiorino G, Gatti S, Jonkers D, Kierkus J, Katsanos KH, Melgar S, Yuksel ES, Whelan K, Wine E, Gerasimidis K. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. J Crohns Colitis 2017;11:1407-19. [PMID: 28961811 DOI: 10.1093/ecco-jcc/jjx109] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
378 Veereman G, Hauser B, De Greef E, Devreker T, Huysentruyt K, Lemmens R, Vandenplas Y. Reflections on treatment of IBD in children and adolescents. Immunopharmacol Immunotoxicol 2018;40:461-4. [PMID: 30040512 DOI: 10.1080/08923973.2018.1474922] [Reference Citation Analysis]
379 Kahn SA, Lin CW, Ozbay B, Wang A, Chao J, Skup M. Indirect Costs and Family Burden of Pediatric Crohn's Disease in the United States. Inflamm Bowel Dis 2017;23:2089-96. [PMID: 28961604 DOI: 10.1097/MIB.0000000000001268] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
380 Wang XQ, Xiao Y, Xu X, Yu Y, Shan CY, Guo Y, Gong L, Zhou T, Gao SS, Yuan YZ, Wang XJ, Xu CD. Study of disease phenotype and its association with prognosis of paediatric inflammatory bowel disease in China. BMC Pediatr. 2018;18:229. [PMID: 30001197 DOI: 10.1186/s12887-018-1212-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
381 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e35-63. [PMID: 31294379 DOI: 10.1093/jcag/gwz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
382 Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2018;12:797-810. [DOI: 10.1080/17474124.2018.1494573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
383 Wall CL, Gearry RB, Day AS. Treatment of Active Crohn's Disease with Exclusive and Partial Enteral Nutrition: A Pilot Study in Adults. Inflamm Intest Dis 2018;2:219-27. [PMID: 30221149 DOI: 10.1159/000489630] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
384 Chouliaras G, Mantzou A, Margoni D, Tsilifis N, Pervanidou P, Panayotou I, Kanaka-Gantenbein C, Chrousos GP, Roma-Giannikou E. Body height in paediatric inflammatory bowel diseases: A structural equation model analysis. Eur J Clin Invest 2018;48:e12969. [PMID: 29893990 DOI: 10.1111/eci.12969] [Reference Citation Analysis]
385 Church PC, Hyams J, Ruemmele F, de Ridder L, Turner D, Griffiths AM. The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World. Can J Gastroenterol Hepatol 2018;2018:3190548. [PMID: 30009157 DOI: 10.1155/2018/3190548] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
386 Shim JO, Jeen YT. The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn's Disease. Gut Liver 2018;12:221-2. [PMID: 29724086 DOI: 10.5009/gnl18112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
387 Sigall Boneh R, Sarbagili Shabat C, Yanai H, Chermesh I, Ben Avraham S, Boaz M, Levine A. Dietary Therapy With the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy. J Crohns Colitis. 2017;11:1205-1212. [PMID: 28525622 DOI: 10.1093/ecco-jcc/jjx071] [Cited by in Crossref: 63] [Cited by in F6Publishing: 73] [Article Influence: 15.8] [Reference Citation Analysis]
388 Timmer A, Stark R, Peplies J, Classen M, Laass MW, Koletzko S. Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: a survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset. Eur J Gastroenterol Hepatol 2017;29:1276-83. [PMID: 28877085 DOI: 10.1097/MEG.0000000000000956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
389 Shaikhkhalil AK, Boyle B, Smith J, Dotson JL, Donegan A, Kim SC, Maltz RM, Crandall W. Using Quality Improvement to Increase Utilization of Enteral Therapy in Pediatric Crohn Disease: Results and Outcomes. Journal of Pediatric Gastroenterology & Nutrition 2018;66:909-14. [DOI: 10.1097/mpg.0000000000001879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
390 Duncan H, Painesi A, Buchanan E, McGrogan P, Gerasimidis K, Walker G, Haddock G, Russell RK. Percutaneous endoscopic gastrostomy placement in paediatric Crohn's disease patients contributes to both improved nutrition and growth. Acta Paediatr 2018;107:1094-9. [PMID: 29423918 DOI: 10.1111/apa.14268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
391 Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1473-82. [PMID: 28617758 DOI: 10.1097/MIB.0000000000001170] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
392 Herman Y, Rinawi F, Rothschild B, Nir O, Shamir R, Assa A. The Characteristics and Long-term Outcomes of Pediatric Crohn's Disease Patients with Perianal Disease. Inflamm Bowel Dis 2017;23:1659-65. [PMID: 28590344 DOI: 10.1097/MIB.0000000000001171] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
393 Wauters L, Smets F, De Greef E, Bontems P, Hoffman I, Hauser B, Alliet P, Arts W, Peeters H, Van Biervliet S, Paquot I, Van de Vijver E, De Vos M, Bossuyt P, Rahier JF, Dewit O, Moreels T, Franchimont D, Muls V, Fontaine F, Louis E, Coche JC, Baert F, Paul J, Vermeire S, Veereman G. Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO). Inflamm Bowel Dis 2017;23:1584-91. [PMID: 28696956 DOI: 10.1097/MIB.0000000000001193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
394 Bryant RV, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak KL, Kucharzik T, Atkinson NSS, Asthana A, Gibson PR. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut 2018;67:973-85. [PMID: 29437914 DOI: 10.1136/gutjnl-2017-315655] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 19.5] [Reference Citation Analysis]
395 Hansen T, Duerksen DR. Enteral Nutrition in the Management of Pediatric and Adult Crohn's Disease. Nutrients 2018;10:E537. [PMID: 29701656 DOI: 10.3390/nu10050537] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
396 Cozijnsen MA, Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Paediatr Drugs 2018;20:19-28. [PMID: 29079905 DOI: 10.1007/s40272-017-0266-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
397 Assa A, Amitai M, Greer ML, Castro DA, Kuint RC, Martínez-León M, Herman-Sucharska I, Coppenrath E, Anupindi S, Towbin A, Moote D, Konen O, Pratt LT, Griffiths A, Turner D; ImageKids Study Group. Perianal Pediatric Crohn Disease Is Associated With a Distinct Phenotype and Greater Inflammatory Burden. J Pediatr Gastroenterol Nutr 2017;65:293-8. [PMID: 28362690 DOI: 10.1097/MPG.0000000000001484] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
398 Gravina AG, Dallio M, Masarone M, Rosato V, Aglitti A, Persico M, Loguercio C, Federico A. Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. Oxid Med Cell Longev 2018;2018:2568569. [PMID: 29849875 DOI: 10.1155/2018/2568569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
399 Kansen HM, van Rheenen PF, Houwen RHJ, Tjon A Ten W, Damen GM, Kindermann A, Escher JC, Wolters VM; Kids with Crohnʼs, Colitis (KiCC) Working Group for Collaborative Paediatric IBD Research in the Netherlands. Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators. J Pediatr Gastroenterol Nutr 2017;65:425-9. [PMID: 28945207 DOI: 10.1097/MPG.0000000000001551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
400 Carman N, Mack DR, Benchimol EI. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0623-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
401 Corbera-Hincapie M, Beasley GL. A Challenging Treatment Decision for a Rare Association: Case Report of Familial Turcot Syndrome With Fistulizing Crohn's Disease. Front Pediatr 2018;6:83. [PMID: 29670872 DOI: 10.3389/fped.2018.00083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
402 Bolia R, Rosenbaum J, Schildkraut V, Hardikar W, Oliver M, Cameron D, Alex G. Secondary Loss of Response to Infliximab in Pediatric Crohn Disease: Does It Matter How and When We Start? Journal of Pediatric Gastroenterology & Nutrition 2018;66:637-40. [DOI: 10.1097/mpg.0000000000001742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
403 Miele E, Shamir R, Aloi M, Assa A, Braegger C, Bronsky J, de Ridder L, Escher JC, Hojsak I, Kolaček S, Koletzko S, Levine A, Lionetti P, Martinelli M, Ruemmele F, Russell RK, Boneh RS, van Limbergen J, Veereman G, Staiano A. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology & Nutrition 2018;66:687-708. [DOI: 10.1097/mpg.0000000000001896] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 14.8] [Reference Citation Analysis]
404 Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018;4:CD000542. [PMID: 29607496 DOI: 10.1002/14651858.CD000542.pub3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
405 Feasel-aklilu S, Roberts K, Ziegler J. Parenteral Nutrition–Dependent Patient With a History of Crohn's Disease Complicated by Central Line–Associated Bloodstream Infections. Topics in Clinical Nutrition 2018;33:144-55. [DOI: 10.1097/tin.0000000000000137] [Reference Citation Analysis]
406 Walters TD, Faubion WA, Griffiths AM, Baldassano RN, Escher J, Ruemmele FM, Hyams JS, Lazar A, Eichner S, Huang B, Li Y, Thakkar RB. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease. Inflamm Bowel Dis 2017;23:967-75. [PMID: 28301428 DOI: 10.1097/MIB.0000000000001075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
407 Fabian O, Hradsky O, Drskova T, Mikus F, Zamecnik J, Bronsky J. Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis. Dig Dis Sci 2018;63:1811-8. [PMID: 29541900 DOI: 10.1007/s10620-018-5018-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
408 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-planella E, Guerra I, Gisbert JP, López-sanromán A. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018;41:205-21. [DOI: 10.1016/j.gastre.2018.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
409 Giugliano FP, Strisciuglio C, Martinelli M, Andreozzi M, Cenni S, Campione S, D’armiento M, Staiano A, Miele E. Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. Digestive and Liver Disease 2018;50:240-6. [DOI: 10.1016/j.dld.2017.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
410 Ling J, Buurman D, Ravikumara M, Mews C, Thacker K, Grover Z. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn’s Disease. Dig Dis Sci 2018;63:1003-10. [DOI: 10.1007/s10620-018-4969-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
411 von Allmen D. Pediatric Crohn's Disease. Clin Colon Rectal Surg 2018;31:80-8. [PMID: 29487490 DOI: 10.1055/s-0037-1609022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
412 Adler J, Dong S, Eder SJ, Dombkowski KJ; ImproveCareNow Pediatric IBD Learning Health System. Perianal Crohn Disease in a Large Multicenter Pediatric Collaborative. J Pediatr Gastroenterol Nutr 2017;64:e117-24. [PMID: 27801750 DOI: 10.1097/MPG.0000000000001447] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
413 Diederen K, de Ridder L, van Rheenen P, Wolters VM, Mearin ML, Damen GM, de Meij TG, van Wering H, Tseng LA, Oomen MW, de Jong JR, Sloots CE, Benninga MA, Kindermann A. Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis. Inflamm Bowel Dis 2017;23:272-82. [PMID: 28079626 DOI: 10.1097/MIB.0000000000000999] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
414 Amil-Dias J, Kolacek S, Turner D, Pærregaard A, Rintala R, Afzal NA, Karolewska-Bochenek K, Bronsky J, Chong S, Fell J, Hojsak I, Hugot JP, Koletzko S, Kumar D, Lazowska-Przeorek I, Lillehei C, Lionetti P, Martin-de-Carpi J, Pakarinen M, Ruemmele FM, Shaoul R, Spray C, Staiano A, Sugarman I, Wilson DC, Winter H, Kolho KL; IBD Working Group of ESPGHAN (IBD Porto Group). Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2017;64:818-35. [PMID: 28267075 DOI: 10.1097/MPG.0000000000001562] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
415 Kang B, Choi SY, Choi YO, Kim M, Kim K, Lee J, Choe YH. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn’s Disease Patients Treated With Combined Immunosuppressive Therapy. Journal of Crohn's and Colitis 2018;12:644-52. [DOI: 10.1093/ecco-jcc/jjy021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
416 Shaikhkhalil AK, Crandall W. Enteral Nutrition for Pediatric Crohn's Disease: An Underutilized Therapy. Nutr Clin Pract 2018;33:493-509. [PMID: 29446858 DOI: 10.1002/ncp.10011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
417 Ashton JJ, Gavin J, Beattie RM. Exclusive enteral nutrition in Crohn's disease: Evidence and practicalities. Clin Nutr. 2019;38:80-89. [PMID: 29398336 DOI: 10.1016/j.clnu.2018.01.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
418 Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:453-60. [PMID: 28129288 DOI: 10.1097/MIB.0000000000001021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
419 Merrick VM, Mortier K, Williams LJ, Muhammed R, Auth MK, Elawad M, Fell JM, Beattie RM, Loganathan S, Torrente F, Morris M, Charlton C, Croft NM, Rodrigues A, Furman M, Vadamalayan B, Jenkins H, Zamvar V, Mitton SG, Chong S, Cosgrove M, Akobeng A, Wilson DC, Russell RK. Real-life Anti-tumor Necrosis Factor Experience in More Than 500 Patients: High Co-immunosuppression Rates But Low Rates of Quantifying Treatment Response. Journal of Pediatric Gastroenterology & Nutrition 2018;66:274-80. [DOI: 10.1097/mpg.0000000000001679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
420 Navas-lópez VM, Pujol-muncunill G, Llerena E, Navalón Rubio M, Gil-ortega D, Varea-calderón V, Sierra Salinas C, Martin-de-carpi J. A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease. Anales de Pediatría (English Edition) 2018;88:89-99. [DOI: 10.1016/j.anpede.2017.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
421 Dunn KA, Moore-Connors J, MacIntyre B, Stadnyk AW, Thomas NA, Noble A, Mahdi G, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. Early Changes in Microbial Community Structure Are Associated with Sustained Remission After Nutritional Treatment of Pediatric Crohn's Disease. Inflamm Bowel Dis. 2016;22:2853-2862. [PMID: 27805918 DOI: 10.1097/mib.0000000000000956] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
422 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
423 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
424 Alhagamhmad MH. Enteral Nutrition in the Management of Crohn's Disease: Reviewing Mechanisms of Actions and Highlighting Potential Venues for Enhancing the Efficacy. Nutr Clin Pract 2018;33:483-92. [PMID: 29323428 DOI: 10.1002/ncp.10004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
425 Jung D, Lee S, Jeong I, Oh SH, Kim KM. Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2017;20:236-43. [PMID: 29302505 DOI: 10.5223/pghn.2017.20.4.236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Qiu K, Liao X, Wu R, Huang K, Fang J, Zhou D. X-linked Hyper-IgM Syndrome: A Phenotype of Crohn's Disease with Hemophagocytic Lymphohistiocytosis. Pediatric Hematology and Oncology 2017;34:428-34. [DOI: 10.1080/08880018.2017.1409301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
427 Gavin J, Ashton JJ, Heather N, Marino LV, Beattie RM. Nutritional support in paediatric Crohn's disease: outcome at 12 months. Acta Paediatr 2018;107:156-62. [PMID: 28901585 DOI: 10.1111/apa.14075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
428 De Greef E, Hoffman I, Smets F, Van Biervliet S, Bontems P, Hauser B, Paquot I, Alliet P, Arts W, Dewit O, De Vos M, Baert F, Bossuyt P, Rahier JF, Franchimont D, Vermeire S, Fontaine F, Louis E, Coche JC, Veereman G; IBD working group of BESPGHAN, BIRD. Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up. J Pediatr Gastroenterol Nutr 2016;63:253-8. [PMID: 26835906 DOI: 10.1097/MPG.0000000000001132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
429 Angelino G, De Angelis P, Faraci S, Rea F, Romeo EF, Torroni F, Tambucci R, Claps A, Francalanci P, Chiriaco M, Di Matteo G, Cancrini C, Palma P, D'argenio P, Dall'oglio L, Rossi P, Finocchi A. Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience. Pediatr Allergy Immunol 2017;28:801-9. [DOI: 10.1111/pai.12814] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
430 Corica D, Romano C. Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. J Clin Gastroenterol. 2017;51:100-110. [PMID: 27636407 DOI: 10.1097/mcg.0000000000000696] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
431 Ballester Ferré MP, Boscá-Watts MM, Mínguez Pérez M. Crohn's disease. Med Clin (Barc) 2018;151:26-33. [PMID: 29246562 DOI: 10.1016/j.medcli.2017.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
432 van Hoeve K, Hoffman I, Vermeire S. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opinion on Drug Safety 2018;17:185-96. [DOI: 10.1080/14740338.2018.1413090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
433 Heida A, Dijkstra A, Muller Kobold A, Rossen JW, Kindermann A, Kokke F, de Meij T, Norbruis O, Weersma RK, Wessels M, Hummel T, Escher J, van Wering H, Hendriks D, Mearin L, Groen H, Verkade HJ, van Rheenen PF. Efficacy of Home Telemonitoring versus Conventional Follow-up: A Randomized Controlled Trial among Teenagers with Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018;12:432-41. [DOI: 10.1093/ecco-jcc/jjx169] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
434 Limketkai BN, Wolf A, Parian AM. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2018;47:155-177. [PMID: 29413010 DOI: 10.1016/j.gtc.2017.09.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
435 de Laffolie J, Laass MW, Scholz D, Zimmer KP, Buderus S; CEDATA-GPGE Study Group . Prevalence of Anemia in Pediatric IBD Patients and Impact on Disease Severity: Results of the Pediatric IBD-Registry CEDATA-GPGE®. Gastroenterol Res Pract 2017;2017:8424628. [PMID: 29358946 DOI: 10.1155/2017/8424628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
436 Wilson DC, Russell RK. Overview of paediatric IBD. Seminars in Pediatric Surgery 2017;26:344-8. [DOI: 10.1053/j.sempedsurg.2017.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
437 Zalieckas JM. Treatment of perianal Crohn’s disease. Seminars in Pediatric Surgery 2017;26:391-7. [DOI: 10.1053/j.sempedsurg.2017.10.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
438 Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol 2018;53:172-80. [PMID: 29192347 DOI: 10.1007/s00535-017-1416-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
439 Schwerd T, Uhlig HH. Chronisch-entzündliche Darmerkrankung und Immundefekte: Klinische Präsentationen und diagnostische Möglichkeiten. Monatsschr Kinderheilkd 2017;165:1092-101. [DOI: 10.1007/s00112-017-0393-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
440 Dipasquale V, Romano C. Pharmacological treatments and infectious diseases in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2018;12:237-47. [PMID: 28994306 DOI: 10.1080/17474124.2018.1391091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
441 Lee WS, Azmi N, Ng RT, Ong SY, Ponnampalavanar SS, Mahadeva S, Hilmi I. Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy. Intest Res 2017;15:524-8. [PMID: 29142521 DOI: 10.5217/ir.2017.15.4.524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
442 McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL. Review article: The gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther. 2018;47:26-42. [PMID: 29034981 DOI: 10.1111/apt.14384] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 22.8] [Reference Citation Analysis]
443 Gong D, Yu X, Wang L, Kong L, Gong X, Dong Q. Exclusive Enteral Nutrition Induces Remission in Pediatric Crohn's Disease via Modulation of the Gut Microbiota. Biomed Res Int 2017;2017:8102589. [PMID: 29124070 DOI: 10.1155/2017/8102589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
444 Day AS, Brown SC. The Adjunctive Role of Nutritional Therapy in the Management of Phlegmon in Two Children with Crohn's Disease. Front Pediatr 2017;5:199. [PMID: 28979892 DOI: 10.3389/fped.2017.00199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
445 Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349-355. [PMID: 29126502 DOI: 10.1053/j.sempedsurg.2017.10.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 94] [Article Influence: 13.8] [Reference Citation Analysis]
446 Baldwin KR, Kaplan JL. Medical management of pediatric inflammatory bowel disease. Semin Pediatr Surg 2017;26:360-6. [PMID: 29126504 DOI: 10.1053/j.sempedsurg.2017.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
447 Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673-692. [PMID: 29132528 DOI: 10.1016/j.pop.2017.07.010] [Cited by in Crossref: 127] [Cited by in F6Publishing: 170] [Article Influence: 25.4] [Reference Citation Analysis]
448 Lane ER, Lee D, Suskind DL. Dietary Therapies in Pediatric Inflammatory Bowel Disease: An Evolving Inflammatory Bowel Disease Paradigm. Gastroenterol Clin North Am 2017;46:731-44. [PMID: 29173518 DOI: 10.1016/j.gtc.2017.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
449 Crook K. Development of a nurse-led paediatric inflammatory bowel disease service. Gastrointestinal Nursing 2017;15:34-40. [DOI: 10.12968/gasn.2017.15.8.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
450 Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. The Lancet Child & Adolescent Health 2017;1:147-58. [DOI: 10.1016/s2352-4642(17)30017-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
451 Oz HS. Nutrients, Infectious and Inflammatory Diseases. Nutrients 2017;9:E1085. [PMID: 28973995 DOI: 10.3390/nu9101085] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
452 Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ 2017;358:j3951. [PMID: 28931512 DOI: 10.1136/bmj.j3951] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 13.4] [Reference Citation Analysis]
453 Issokson K. Living on Liquids: Surviving and Thriving on Exclusive Enteral Nutrition. Am J Gastroenterol 2017;112:1491-2. [PMID: 28872151 DOI: 10.1038/ajg.2017.269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
454 Navas-lópez V, Ramos-rueda N, Pujol-muncunill G, Martín de Carpi J. Metotrexato en la enfermedad inflamatoria intestinal pediátrica. Enfermedad Inflamatoria Intestinal al Día 2017;16:127-37. [DOI: 10.1016/j.eii.2016.12.003] [Reference Citation Analysis]
455 Assa A, Shamir R. Exclusive enteral nutrition for inducing remission in inflammatory bowel disease in paediatric patients. Current Opinion in Clinical Nutrition & Metabolic Care 2017;20:384-9. [DOI: 10.1097/mco.0000000000000402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
456 Wahbeh GT, Ward BT, Lee DY, Giefer MJ, Suskind DL. Lack of Mucosal Healing From Modified Specific Carbohydrate Diet in Pediatric Patients With Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2017;65:289-92. [DOI: 10.1097/mpg.0000000000001619] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
457 Aleksandrova K, Romero-Mosquera B, Hernandez V. Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention. Nutrients 2017;9:E962. [PMID: 28867793 DOI: 10.3390/nu9090962] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 16.6] [Reference Citation Analysis]
458 Maratova K, Hradsky O, Matyskova J, Copova I, Soucek O, Sumnik Z, Bronsky J. Musculoskeletal system in children and adolescents with inflammatory bowel disease: normal muscle force, decreased trabecular bone mineral density and low prevalence of vertebral fractures. Eur J Pediatr 2017;176:1355-63. [PMID: 28840427 DOI: 10.1007/s00431-017-2988-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
459 Ohem J, Hradsky O, Zarubova K, Copova I, Bukovska P, Prusa R, Malickova K, Bronsky J. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors. Dig Dis 2018;36:40-8. [PMID: 28817809 DOI: 10.1159/000477962] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
460 Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li Ferry S. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. Aliment Pharmacol Ther 2017;46:645-56. [PMID: 28815649 DOI: 10.1111/apt.14253] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 15.8] [Reference Citation Analysis]
461 Guariso G, Gasparetto M. Treating children with inflammatory bowel disease: Current and new perspectives. World J Gastroenterol 2017; 23(30): 5469-5485 [PMID: 28852307 DOI: 10.3748/wjg.v23.i30.5469] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
462 Luo Y, Yu J, Lou J, Fang Y, Chen J. Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease. Gastroenterol Res Pract 2017;2017:6595048. [PMID: 28928769 DOI: 10.1155/2017/6595048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
463 Gatti S, Galeazzi T, Franceschini E, Annibali R, Albano V, Verma AK, De Angelis M, Lionetti ME, Catassi C. Effects of the Exclusive Enteral Nutrition on the Microbiota Profile of Patients with Crohn's Disease: A Systematic Review. Nutrients. 2017;9:832. [PMID: 28777338 DOI: 10.3390/nu9080832] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
464 Deneau MR, El-Matary W, Valentino PL, Abdou R, Alqoaer K, Amin M, Amir AZ, Auth M, Bazerbachi F, Broderick A, Chan A, Cotter J, Doan S, El-Youssef M, Ferrari F, Furuya KN, Gottrand M, Gottrand F, Gupta N, Homan M, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Ledder O, Mack C, Martinez M, Miloh T, Mohan P, O'Cathain N, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Jensen MK. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology 2017;66:518-27. [PMID: 28390159 DOI: 10.1002/hep.29204] [Cited by in Crossref: 113] [Cited by in F6Publishing: 91] [Article Influence: 22.6] [Reference Citation Analysis]
465 Lawrence SJ, Sadarangani M, Jacobson K. Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review. Front Pediatr 2017;5:161. [PMID: 28791279 DOI: 10.3389/fped.2017.00161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
466 Ashton JJ, Colquhoun CM, Cleary DW, Coelho T, Haggarty R, Mulder I, Batra A, Afzal NA, Beattie RM, Scott KP, Ennis S. 16S sequencing and functional analysis of the fecal microbiome during treatment of newly diagnosed pediatric inflammatory bowel disease. Medicine (Baltimore) 2017;96:e7347. [PMID: 28658154 DOI: 10.1097/MD.0000000000007347] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
467 Yerushalmy-feler A, Ron Y, Barnea E, Nachum A, Matalon S, Dali-levy M, Dotan I, Cohen S. Adolescent transition clinic in inflammatory bowel disease: quantitative assessment of self-efficacy skills. European Journal of Gastroenterology & Hepatology 2017;29:831-7. [DOI: 10.1097/meg.0000000000000864] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
468 Gut G, Ben-Tov A, Lahad A, Soferman R, Cohen S, Tauman R, Sivan Y. Pulmonary functions in children with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2016;28:708-13. [PMID: 26862933 DOI: 10.1097/MEG.0000000000000606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
469 Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr 2018;66:84-9. [PMID: 28604509 DOI: 10.1097/MPG.0000000000001641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
470 Ishige T, Tomomasa T, Tajiri H, Yoden A; Japanese Study Group for Pediatric Crohn's Disease. Japanese physicians' attitudes towards enteral nutrition treatment for pediatric patients with Crohn's disease: a questionnaire survey. Intest Res 2017;15:345-51. [PMID: 28670231 DOI: 10.5217/ir.2017.15.3.345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
471 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
472 Yang Q, Gao X, Chen H, Li M, Wu X, Zhi M, Lan P, Hu P. Efficacy of exclusive enteral nutrition in complicated Crohn's disease. Scand J Gastroenterol. 2017;52:995-1001. [PMID: 28598298 DOI: 10.1080/00365521.2017.1335770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
473 Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT, McKiernan PJ, Murray CD, Sebastian S, Smith M, Whitley L, Williams L, Russell RK, McCartney SA, Lindsay JO. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut 2017;66:988-1000. [PMID: 28228488 DOI: 10.1136/gutjnl-2016-313000] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
474 Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017;357:j2083. [PMID: 28566467 DOI: 10.1136/bmj.j2083] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
475 Schulman JM, Pritzker L, Shaoul R. Maintenance of Remission with Partial Enteral Nutrition Therapy in Pediatric Crohn's Disease: A Retrospective Study. Can J Gastroenterol Hepatol 2017;2017:5873158. [PMID: 28567370 DOI: 10.1155/2017/5873158] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
476 Truffinet O, Martinez-vinson C, Guerriero E, Hugot J, Viala J. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. Journal of Pediatric Gastroenterology & Nutrition 2017;64:721-5. [DOI: 10.1097/mpg.0000000000001338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
477 MacLellan A, Moore-Connors J, Grant S, Cahill L, Langille MGI, Van Limbergen J. The Impact of Exclusive Enteral Nutrition (EEN) on the Gut Microbiome in Crohn's Disease: A Review. Nutrients 2017;9:E0447. [PMID: 28468301 DOI: 10.3390/nu9050447] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
478 Martino JV, Van Limbergen J, Cahill LE. The Role of Carrageenan and Carboxymethylcellulose in the Development of Intestinal Inflammation. Front Pediatr 2017;5:96. [PMID: 28507982 DOI: 10.3389/fped.2017.00096] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
479 Valenti S, Gallizzi R, De Vivo D, Romano C. Intestinal Behçet and Crohn's disease: two sides of the same coin. Pediatr Rheumatol Online J 2017;15:33. [PMID: 28427473 DOI: 10.1186/s12969-017-0162-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
480 Cohen SA, Aloi M, Arumugam R, Baker R, Bax K, Kierkuś J, Koletzko S, Lionetti P, Persson T, Eklund S. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children. Curr Med Res Opin 2017;33:1261-8. [PMID: 28420280 DOI: 10.1080/03007995.2017.1313213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
481 Sundqvist T, Stenhammar L, Tjellström B, Magnusson KE, Forslund T, Högberg L. Oral immunoglobulin treatment improved intestinal permeability in children with active Crohn's disease. Acta Paediatr 2017;106:647-53. [PMID: 28107568 DOI: 10.1111/apa.13747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
482 Cohen-dolev N, Sladek M, Hussey S, Turner D, Veres G, Koletzko S, Martin de Carpi J, Staiano A, Shaoul R, Lionetti P, Amil Dias J, Paerregaard A, Nuti F, Pfeffer Gik T, Ziv-baran T, Ben Avraham Shulman S, Sarbagili Shabat C, Sigall Boneh R, Russell RK, Levine A. Differences in Outcomes Over Time With Exclusive Enteral Nutrition Compared With Steroids in Children With Mild to Moderate Crohn’s Disease: Results From the GROWTH CD Study. Journal of Crohn's and Colitis 2018;12:306-12. [DOI: 10.1093/ecco-jcc/jjx150] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
483 Kim S. Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr 2017;20:14-21. [PMID: 28401051 DOI: 10.5223/pghn.2017.20.1.14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
484 Chuong KH, Mack DR, Stintzi A, O'Doherty KC. Human Microbiome and Learning Healthcare Systems: Integrating Research and Precision Medicine for Inflammatory Bowel Disease. OMICS 2018;22:119-26. [PMID: 28282257 DOI: 10.1089/omi.2016.0185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
485 Viala J, Michaud L, Bellaiche M, Lachaux A. [When and how should small-bowel capsule endoscopy be used in children?]. Arch Pediatr 2017;24:391-8. [PMID: 28279616 DOI: 10.1016/j.arcped.2017.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
486 Mosztbacher D, Farkas N, Solymár M, Pár G, Bajor J, Szűcs &, Czimmer J, Márta K, Mikó A, Rumbus Z, Varjú P, Hegyi P, Párniczky A. Restoration of energy level in the early phase of acute pediatric pancreatitis. World J Gastroenterol 2017; 23(6): 957-963 [PMID: 28246469 DOI: 10.3748/wjg.v23.i6.957] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
487 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
488 Dijkstra A, Touw DJ, van Rheenen PF. Simple Urine Test to Evaluate Adherence to Oral 5-ASA in Teenagers With Ulcerative Colitis: Proof of Concept. J Pediatr Gastroenterol Nutr 2017;65:416-9. [PMID: 28169975 DOI: 10.1097/MPG.0000000000001541] [Reference Citation Analysis]
489 Barlow JJ, Hawthorne AB. Crohn's disease for the general physician: management. Br J Hosp Med (Lond) 2017;78:77-81. [PMID: 28165796 DOI: 10.12968/hmed.2017.78.2.77] [Reference Citation Analysis]
490 Barlow JJ, Hawthorne AB. Crohn's disease for the general physician: presentation and investigations. Br J Hosp Med (Lond) 2017;78:72-6. [PMID: 28165787 DOI: 10.12968/hmed.2017.78.2.72] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
491 D’arcangelo G, Aloi M. Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management. Pediatr Drugs 2017;19:113-20. [DOI: 10.1007/s40272-017-0213-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
492 Dupont-lucas C, Grandjean-blanchet C, Leduc B, Tripcovici M, Larocque C, Gervais F, Jantchou P, Amre D, Deslandres C. Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:298-303. [DOI: 10.1097/mib.0000000000001014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
493 Al-Sarkhy AA. Variation in inflammatory bowel disease care among saudi pediatric gastroenterologists. Saudi J Gastroenterol 2017;23:45-51. [PMID: 28139500 DOI: 10.4103/1319-3767.199115] [Reference Citation Analysis]
494 Schwerd T, Koletzko S. Chronisch entzündliche Darmerkrankungen. Monatsschr Kinderheilkd 2017;165:257-70. [DOI: 10.1007/s00112-017-0243-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
495 Diederen K, Hoekman DR, Leek A, Wolters VM, Hummel TZ, de Meij TG, Koot BGP, Tabbers MM, Benninga MA, Kindermann A. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther 2017;45:951-60. [DOI: 10.1111/apt.13950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
496 El Mouzan MI, Al Mofarreh MA, Saadah OI, Al-Hussaini AA, Al-Saleem KA, Al Mehaidib AI. Impact of pediatric inflammatory bowel disease on linear growth: Data from a national cohort study in Saudi Arabia. Saudi J Gastroenterol 2016;22:106-8. [PMID: 26997215 DOI: 10.4103/1319-3767.178524] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
497 Guz-Mark A, Rinawi F, Egotubov O, Shimon I, Shamir R, Assa A. Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthood. Dig Liver Dis 2017;49:639-42. [PMID: 28179094 DOI: 10.1016/j.dld.2017.01.151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
498 Svolos V, Gerasimidis K, Buchanan E, Curtis L, Garrick V, Hay J, Laird S, Munro J, Gaya DR, Russell RK, Hansen R. Dietary treatment of Crohn's disease: perceptions of families with children treated by exclusive enteral nutrition, a questionnaire survey. BMC Gastroenterol 2017;17:14. [PMID: 28103809 DOI: 10.1186/s12876-016-0564-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
499 Gale G, Sigurdsson GV, Östman S, Malmborg P, Högkil K, Hasséus B, Jontell M, Saalman R. Does Crohn's Disease with Concomitant Orofacial Granulomatosis Represent a Distinctive Disease Subtype? Inflamm Bowel Dis 2016;22:1071-7. [PMID: 26829409 DOI: 10.1097/MIB.0000000000000670] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
500 Brooks AJ, Smith PJ, Lindsay JO. Monitoring adolescents and young people with inflammatory bowel disease during transition to adult healthcare. Frontline Gastroenterol 2018;9:37-44. [PMID: 29484159 DOI: 10.1136/flgastro-2016-100747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
501 Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Bischoff SC. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017;36:321-47. [PMID: 28131521 DOI: 10.1016/j.clnu.2016.12.027] [Cited by in Crossref: 254] [Cited by in F6Publishing: 279] [Article Influence: 42.3] [Reference Citation Analysis]
502 Dubinsky MC, Rosh J, Faubion WA Jr, Kierkus J, Ruemmele F, Hyams JS, Eichner S, Li Y, Huang B, Mostafa NM, Lazar A, Thakkar RB. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis 2016;22:886-93. [PMID: 26950307 DOI: 10.1097/MIB.0000000000000715] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
503 Cozijnsen MA, van Pieterson M, Samsom JN, Escher JC, de Ridder L. Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol 2016;3:e000123. [PMID: 28090335 DOI: 10.1136/bmjgast-2016-000123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
504 Altowati MA, Jones AP, Hickey H, Williamson PR, Barakat FM, Plaatjies NC, Hardwick B, Russell RK, Jaki T, Ahmed SF, Sanderson IR. Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease. Pilot Feasibility Stud 2016;2:71. [PMID: 27965886 DOI: 10.1186/s40814-016-0112-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
505 Kim HJ, Kim Y, Cho JM, Oh SH, Kim KM. Therapeutic Efficacy of Oral Enteral Nutrition in Pediatric Crohn's Disease: A Single Center Non-Comparative Retrospective Study. Yonsei Med J 2016;57:1185-91. [PMID: 27401650 DOI: 10.3349/ymj.2016.57.5.1185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
506 Winter RW, Burakoff R. How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies. Expert Rev Gastroenterol Hepatol 2017;11:95-7. [PMID: 27900879 DOI: 10.1080/17474124.2017.1266935] [Reference Citation Analysis]
507 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 615] [Cited by in F6Publishing: 786] [Article Influence: 102.5] [Reference Citation Analysis]
508 Kapoor A, Bhatia V, Sibal A. Pediatric inflammatory bowel disease. Indian Pediatr 2016;53:993-1002. [DOI: 10.1007/s13312-016-0975-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
509 Lafferty L, Tuohy M, Carey A, Sugrue S, Hurley M, Hussey S. Outcomes of exclusive enteral nutrition in paediatric Crohn’s disease. Eur J Clin Nutr 2017;71:185-91. [DOI: 10.1038/ejcn.2016.210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
510 Spekhorst LM, Hummel TZ, Benninga MA, van Rheenen PF, Kindermann A. Adherence to Oral Maintenance Treatment in Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016;62:264-70. [PMID: 26230905 DOI: 10.1097/MPG.0000000000000924] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
511 Béres NJ, Szabó D, Kocsis D, Szűcs D, Kiss Z, Müller KE, Lendvai G, Kiss A, Arató A, Sziksz E, Vannay Á, Szabó AJ, Veres G. Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:327-35. [PMID: 26752469 DOI: 10.1097/MIB.0000000000000687] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
512 Meijer B, Mulder CJ, van Bodegraven AA, de Boer NKH. How I treat my inflammatory bowel disease-patients with thiopurines? World J Gastrointest Pharmacol Ther 2016; 7(4): 524-530 [PMID: 27867685 DOI: 10.4292/wjgpt.v7.i4.524] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
513 Mutalib M, Bezanti K, Elawad M, Kiparissi F. The role of exclusive enteral nutrition in the management of orofacial granulomatosis in children. World J Pediatr 2016;12:421-4. [DOI: 10.1007/s12519-016-0045-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
514 Atkinson NS, Bryant RV, Dong Y, Maaser C, Kucharzik T, Maconi G, Asthana AK, Blaivas M, Goudie A, Gilja OH. WFUMB Position Paper. Learning Gastrointestinal Ultrasound: Theory and Practice. Ultrasound Med Biol. 2016;42:2732-2742. [PMID: 27742140 DOI: 10.1016/j.ultrasmedbio.2016.08.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
515 Lee W, Briars L, Lee TA, Calip GS, Suda KJ, Schumock GT. Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2410-7. [DOI: 10.1097/mib.0000000000000880] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
516 Bamberger S, Martinez Vinson C, Mohamed D, Viala J, Carel JC, Hugot JP, Simon D. Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. PLoS One 2016;11:e0163126. [PMID: 27636201 DOI: 10.1371/journal.pone.0163126] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
517 Bishop C, Simon H, Suskind D, Lee D, Wahbeh G. Ustekinumab in Pediatric Crohn Disease Patients. Journal of Pediatric Gastroenterology & Nutrition 2016;63:348-51. [DOI: 10.1097/mpg.0000000000001146] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
518 Hukkinen M, Pakarinen MP, Merras-salmio L, Koivusalo A, Rintala R, Kolho K. Fecal calprotectin in the prediction of postoperative recurrence of Crohn's disease in children and adolescents. Journal of Pediatric Surgery 2016;51:1467-72. [DOI: 10.1016/j.jpedsurg.2016.01.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
519 Szűcs D, Béres NJ, Rokonay R, Boros K, Borka K, Kiss Z, Arató A, Szabó AJ, Vannay &, Sziksz E, Bereczki C, Veres G. Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease. World J Gastroenterol 2016; 22(26): 6027-6035 [PMID: 27468194 DOI: 10.3748/wjg.v22.i26.6027] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
520 Trindade E. Pediatric Crohn's Disease and Surgery: Another Tool for the Treatment of a Complex Disease. GE Port J Gastroenterol 2016;23:181-2. [PMID: 28868457 DOI: 10.1016/j.jpge.2016.05.002] [Reference Citation Analysis]
521 Grossi V, Hyams JS. The safety of treatment options for pediatric Crohn’s disease. Expert Opinion on Drug Safety 2016;15:1383-90. [DOI: 10.1080/14740338.2016.1203418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
522 Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. Journal of Pediatric Gastroenterology & Nutrition 2016;63:130-55. [DOI: 10.1097/mpg.0000000000001188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
523 Kolho KL, Ainamo A. Progress in the treatment and outcome of pediatric inflammatory bowel disease patients. Expert Rev Clin Immunol. 2016;12:1337-1345. [PMID: 27322874 DOI: 10.1080/1744666x.2016.1201422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
524 Lourenço R, Azevedo S, Lopes AI. Surgery in Pediatric Crohn Disease: Case Series from a Single Tertiary Referral Center. GE Port J Gastroenterol 2016;23:191-6. [PMID: 28868459 DOI: 10.1016/j.jpge.2016.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
525 Aloi M, Birimberg-schwartz L, Buderus S, Hojsak I, Fell JM, Bronsky J, Veereman G, Koletzko S, Shaoul R, Miele E, Turner D, Russell RK. Treatment Options and Outcomes of Pediatric IBDU Compared with Other IBD Subtypes: A Retrospective Multicenter Study from the IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases 2016;22:1378-83. [DOI: 10.1097/mib.0000000000000767] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
526 Penagini F, Dilillo D, Borsani B, Cococcioni L, Galli E, Bedogni G, Zuin G, Zuccotti GV. Nutrition in Pediatric Inflammatory Bowel Disease: From Etiology to Treatment. A Systematic Review. Nutrients. 2016;8. [PMID: 27258308 DOI: 10.3390/nu8060334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
527 Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach. Inflamm Bowel Dis 2015;21:1993-2003. [PMID: 25966839 DOI: 10.1097/MIB.0000000000000395] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
528 Larsen MD, Baldal ME, Nielsen RG, Nielsen J, Lund K, Nørgård BM. The incidence of Crohn's disease and ulcerative colitis since 1995 in Danish children and adolescents <17 years - based on nationwide registry data. Scand J Gastroenterol 2016;51:1100-5. [PMID: 27160395 DOI: 10.3109/00365521.2016.1172340] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
529 Cozijnsen MA, de Ridder L. Infliximab More Effective in Therapy-Naïve Than in Therapy-Refractory Patients. J Pediatr Gastroenterol Nutr 2015;61:e15. [PMID: 26111298 DOI: 10.1097/MPG.0000000000000884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
530 Davis-Kankanamge CN, Bercaw-Pratt JL, Santos XM, Dietrich JE. Crohn's Disease and Gynecologic Manifestations in Young Women. J Pediatr Adolesc Gynecol 2016;29:582-4. [PMID: 27108229 DOI: 10.1016/j.jpag.2016.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
531 Diederen K, Hoekman DR, Hummel TZ, de Meij TG, Koot BG, Tabbers MM, Vlieger AM, Kindermann A, Benninga MA. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity. Aliment Pharmacol Ther 2016;44:181-8. [PMID: 27110920 DOI: 10.1111/apt.13636] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
532 Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment. ECCOJC 2016;10:1279-86. [DOI: 10.1093/ecco-jcc/jjw086] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
533 Virta LJ, Kautiainen H, Kolho KL. Symptoms suggestive of cow's milk allergy in infancy and pediatric inflammatory bowel disease. Pediatr Allergy Immunol 2016;27:361-7. [PMID: 26887931 DOI: 10.1111/pai.12551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
534 Jelenova D, Prasko J, Ociskova M, Latalova K, Karaskova E, Hruby R, Kamaradova D, Mihal V. Quality of life and parental styles assessed by adolescents suffering from inflammatory bowel diseases and their parents. Neuropsychiatr Dis Treat 2016;12:665-72. [PMID: 27042077 DOI: 10.2147/NDT.S104260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
535 O'Toole A, Moss AC. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep 2015;17:32. [PMID: 26188882 DOI: 10.1007/s11894-015-0453-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
536 Dziechciarz P, Horvath A, Kierkuś J. Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review. J Crohns Colitis 2016;10:1237-44. [PMID: 26995184 DOI: 10.1093/ecco-jcc/jjw077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
537 Schwerd T, Frivolt K, Clavel T, Lagkouvardos I, Katona G, Mayr D, Uhlig HH, Haller D, Koletzko S, Bufler P. Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation. J Allergy Clin Immunol 2016;138:592-6. [PMID: 26987574 DOI: 10.1016/j.jaci.2015.12.1331] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
538 Hradsky O, Copova I, Zarubova K, Nevoral J, Bronsky J. Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids. Dig Dis Sci 2016;61:2041-50. [PMID: 26971092 DOI: 10.1007/s10620-016-4103-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
539 Wasilewski A, Zielińska M, Storr M, Fichna J. Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:1674-82. [PMID: 25822014 DOI: 10.1097/MIB.0000000000000364] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 17.2] [Reference Citation Analysis]
540 Assa A, Avni I, Ben-bassat O, Niv Y, Shamir R. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. Journal of Pediatric Gastroenterology & Nutrition 2016;62:372-7. [DOI: 10.1097/mpg.0000000000000943] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
541 Sarbagili-Shabat C, Sigall-Boneh R, Levine A. Nutritional therapy in inflammatory bowel disease. Curr Opin Gastroenterol. 2015;31:303-308. [PMID: 25887458 DOI: 10.1097/MOG.0000000000000178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
542 Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol 2016; 22(7): 2179-2194 [PMID: 26900283 DOI: 10.3748/wjg.v22.i7.2179] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 68] [Article Influence: 15.7] [Reference Citation Analysis]
543 Buderus S, Scholz D, Behrens R, Classen M, De Laffolie J, Keller KM, Zimmer KP, Koletzko S; CEDATA-GPGE Study Group. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry. Dtsch Arztebl Int 2015;112:121-7. [PMID: 25759978 DOI: 10.3238/arztebl.2015.0121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 31] [Article Influence: 0.7] [Reference Citation Analysis]
544 Larsen MD, Qvist N, Nielsen J, Kjeldsen J, Nielsen RG, Nørgård BM. Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn’s Disease. ECCOJC 2016;10:650-6. [DOI: 10.1093/ecco-jcc/jjw017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
545 Turner D, Koletzko S, Griffiths AM, Hyams J, Dubinsky M, de Ridder L, Escher J, Lionetti P, Cucchiara S, Lentze MJ, Koletzko B, van Rheenen P, Russell RK, Mack D, Veereman G, Vermeire S, Ruemmele F. Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network. Journal of Pediatric Gastroenterology & Nutrition 2016;62:183-7. [DOI: 10.1097/mpg.0000000000001024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
546 Sieczkowska J, Jarzębicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, Oracz G, Meglicka M, Kierkus J. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations. J Crohns Colitis 2016;10:127-32. [PMID: 26721942 DOI: 10.1093/ecco-jcc/jjv233] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 13.0] [Reference Citation Analysis]
547 Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
548 Dolinšek J, Rižnik P, Sabath L, Mičetić-turk D. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease. Wien Klin Wochenschr 2016;128:253-9. [DOI: 10.1007/s00508-015-0915-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
549 Stippler D, Bode V, Fischer M, Kollex K, Rohde E, Tisowsky B, Künstner J, Pahne N. Proposal for a new practicable categorization system for food for special medical purposes – Enteral nutritional products. Clinical Nutrition ESPEN 2015;10:e219-23. [DOI: 10.1016/j.clnesp.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
550 Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
551 Kammermeier J, Morris MA, Garrick V, Furman M, Rodrigues A, Russell RK. Management of Crohn’s disease. Arch Dis Child. 2016;101:475-480. [PMID: 26553907 DOI: 10.1136/archdischild-2014-307217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
552 Scherkenbach LA, Stumpf JL. Methotrexate for the Management of Crohn's Disease in Children. Ann Pharmacother 2016;50:60-9. [PMID: 26511908 DOI: 10.1177/1060028015613527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
553 Serban DE. Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet? Nutr Clin Pract 2015;30:760-79. [DOI: 10.1177/0884533615606898] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
554 Hojsak I, Kolacek S, Hansen LF, Bronsky J, Piekkala M, Lionetti P, Skaba R, Kolho K. Long-term outcomes after elective ileocecal resection in children with active localized Crohn's disease—a multicenter European study. Journal of Pediatric Surgery 2015;50:1630-5. [DOI: 10.1016/j.jpedsurg.2015.03.054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
555 Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. J Intern Med. 2016;279:241-258. [PMID: 26355194 DOI: 10.1111/joim.12413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
556 Oliva S, Cucchiara S, Civitelli F, Casciani E, Di Nardo G, Hassan C, Papoff P, Cohen SA. Colon capsule endoscopy compared with other modalities in the evaluation of pediatric Crohn's disease of the small bowel and colon. Gastrointest Endosc. 2016;83:975-983. [PMID: 26363334 DOI: 10.1016/j.gie.2015.08.070] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
557 Szajewska H. What are the indications for using probiotics in children? Arch Dis Child. 2016;101:398-403. [PMID: 26347386 DOI: 10.1136/archdischild-2015-308656] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
558 García-cabo C, Morís G. Peripheral neuropathy: An underreported neurologic manifestation of inflammatory bowel disease. European Journal of Internal Medicine 2015;26:468-75. [DOI: 10.1016/j.ejim.2015.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
559 Chhaya V, Pollok RCG, Cecil E, Subramanian V, Curcin V, Majeed A, Saxena S. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther 2015;42:990-9. [DOI: 10.1111/apt.13361] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
560 Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L, Grant A, Chehoud C, Bushman FD, Wu GD, Lewis JD. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohnʼs Disease: . Inflammatory Bowel Diseases 2015;21:1786-93. [DOI: 10.1097/mib.0000000000000426] [Cited by in Crossref: 98] [Cited by in F6Publishing: 79] [Article Influence: 14.0] [Reference Citation Analysis]
561 Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Review of Clinical Immunology 2015;11:963-72. [DOI: 10.1586/1744666x.2015.1072048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
562 Van Limbergen J, Haskett J, Griffiths AM, Critch J, Huynh H, Ahmed N, deBruyn JC, Issenman R, El-Matary W, Walters TD, Kluthe C, Roy ME, Sheppard E, Crandall WV, Cohen S, Ruemmele FM, Levine A, Otley AR. Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: a workshop to identify barriers and enablers. Can J Gastroenterol Hepatol 2015;29:351-6. [PMID: 26076398 DOI: 10.1155/2015/509497] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
563 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
564 Grover Z, Lewindon P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. Dig Dis Sci 2015;60:3069-74. [PMID: 26038093 DOI: 10.1007/s10620-015-3722-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
565 Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;60:737-43. [DOI: 10.1097/mpg.0000000000000711] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
566 Kolho K, Korpela K, Jaakkola T, Pichai MVA, Zoetendal EG, Salonen A, de Vos WM. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. American Journal of Gastroenterology 2015;110:921-30. [DOI: 10.1038/ajg.2015.149] [Cited by in Crossref: 120] [Cited by in F6Publishing: 131] [Article Influence: 17.1] [Reference Citation Analysis]
567 Luo Y, Yu J, Zhao H, Lou J, Chen F, Peng K, Chen J. Short-Term Efficacy of Exclusive Enteral Nutrition in Pediatric Crohn's Disease: Practice in China. Gastroenterol Res Pract 2015;2015:428354. [PMID: 26106412 DOI: 10.1155/2015/428354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
568 Mattioli G, Pio L, Arrigo S, Pini Prato A, Montobbio G, Disma NM, Barabino A. Cone-like resection, fistulectomy and mucosal rectal sleeve partial endorectal pull-through in paediatric Crohn's disease with perianal complex fistula. Dig Liver Dis 2015;47:658-62. [PMID: 26048251 DOI: 10.1016/j.dld.2015.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
569 Gallego-Gutiérrez S, Navas-López VM, Kolorz M, Bartosova L, Lukac K, Luque-Pérez S, Núñez-Caro L, García-Galán P, Fernández-Crehuet FG, Blasco-Alonso J, Serrano-Nieto MJ, Sierra-Salinas C. Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn's Disease. J Crohns Colitis 2015;9:676-9. [PMID: 25968582 DOI: 10.1093/ecco-jcc/jjv086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
570 Zeisler B, Hyams JS. Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab. Pediatric Health Med Ther 2015;6:33-40. [PMID: 29388607 DOI: 10.2147/PHMT.S40948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
571 Hojsak I, Mišak Z, Jadrešin O, Močić Pavić A, Kolaček S. Methotrexate is an efficient therapeutic alternative in children with thiopurine-resistant Crohn's disease. Scand J Gastroenterol 2015;50:1208-13. [PMID: 25877164 DOI: 10.3109/00365521.2015.1031166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
572 Diamanti A, Capriati T, Papadatou B, Knafelz D, Bracci F, Corsetti T, Elia D, Torre G. The clinical implications of thalidomide in inflammatory bowel diseases. Expert Rev Clin Immunol. 2015;11:699-708. [PMID: 25865355 DOI: 10.1586/1744666x.2015.1027687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
573 Shi J, Huang Z, Wang Y, Huang Y. The Protective Effects of Exclusive Enteral Nutrition Formulas on Growth Factor Expression and the Proximal Tibial Epiphyseal Growth Plate in a TNBS-Induced IBD Rat Model. Dig Dis Sci 2015;60:1931-40. [DOI: 10.1007/s10620-015-3582-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
574 Kaistha A, Levine J. Inflammatory Bowel Disease: The Classic Gastrointestinal Autoimmune Disease. Current Problems in Pediatric and Adolescent Health Care 2014;44:328-34. [DOI: 10.1016/j.cppeds.2014.10.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
575 Affronti A, Orlando A, Cottone M. An update on medical management on Crohn’s disease. Expert Opin Pharmacother. 2015;16:63-78. [PMID: 25418125 DOI: 10.1517/14656566.2015.981525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
576 Misra SM. Integrative Therapies and Pediatric Inflammatory Bowel Disease: The Current Evidence. Children (Basel) 2014;1:149-65. [PMID: 27417473 DOI: 10.3390/children1020149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
577 Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990-1007.e3. [PMID: 25058236 DOI: 10.1053/j.gastro.2014.07.023] [Cited by in Crossref: 345] [Cited by in F6Publishing: 333] [Article Influence: 43.1] [Reference Citation Analysis]